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Chapter one 
INTRODUCTION AND AIM OF THE STUDY. 
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1.1.1 Historical overview. 
Arginine-vasopressin (AVP) is one of the two hormones released from the posterior 
pituitarYI which is known for being both the antidiuretio hormone and a potent vasopressor. 
The vasopressor action of AVP was first discovered in 1895 when Oliver and Schafer 
found that a crude extract of the pituitary, caused an elevation in blood pressure in dogs', 
when administered intravenously. 
Howell showed in 1898 that it was the posterior lobe of the gland that contained the 
vasopressor substance2, The antidiuretic activity of the posterior pituitary extract was 
discovered in 1913 3 , This opened the possibility for treatment of patients with central 
diabetes insipidus. In 1928 the crude posterior pituitary extract was separated into two 
fractions, "oxytocin" and "vasopressin", with different biological activities4 • tlOxytocin" was 
shown to have an effect on uterus contractions, whereas IIvasopressin" harbored the 
potential to cause a rise in blood pressure, and the antidiuretic effect. 
Chemical analysis of "vasopressinn from different species revealed that two types of 
"vasopressin" eXist; being tllysine vasopressin" and "arginine vasopressin"s. The molecular 
struoture of arginine-vasopressin was eluoidated by Ou Vigneauct'·7. Human ''Vasopressinlt 
was proved to be arginine vasopressin, a nonapeptide with a disulfide bridge between the 
two cysteio acid residues (Fig.1)8. From this moment, the name "vasopressinl! whioh first 
represented an extract of the posterior pituitary was used for its aotive oompound. 
Phe ---Gin 
Tyr Asn 
NH2-Gys -8 -8 -Cys - Pro - L-Arg - Gly 
Figure 1. L-Arginine vasopressin. 
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1.1.2 Vasopressin metabolism. 
The neurohormone AVP is stored in the posterior pituitary from where it is released 
into the ciroulation. It is synthesized in large cells in the supraoptio and paraventricular 
nuclei and transported along the axons in dense granules9,tO,,,. These dense granules are 
deposited in the nerve endings which are situated in close proximity to oapillaries in the 
posterior pituitary'2, On appropriate stimulation, the content of these granules is excreted 
into the blood stream by eXQoytosis'3, 
Besides the AVP released from the pituitary into the circulation, it can also be found 
in several other places in the brain, and in the cerebra spinal fluid I4,16, where it most likely 
serves as a neurotransmitter and a neuromodulatorI6,17,18,19. The exact function is still 
obscure, but growing evidence points to a function of AVP in the preservation of memory 
and in the modulation of central cardiovascular regulation and the 
baro reflex 18,20,21 ,22,23,24,2;;,26 . 
Regulation of AVP excretion from the posterior pituitary depends on several 
influences. In normal physiology the major controlling factor is plasma osmolality20,27,28. A 
rise in plasma osmolality results in an increase in AVP excretion, which causes an 
increase in renal water reabsorption in the collecting ducts29 ,30. In this way AVP is the 
most important hormone involved in the regulation of renal water excretion31 • AVP 
excretion can also be influenced by arterial blood pressure32, total blood volume33,34,36,38, 
plasma angiotensin IIlevels37,38,39,4Q and several other faclors41 ,42,43.44. However, the 
physiologic importance of these factors is not clea(3I,39,4.'),46,47,48, 
Plasma AVP levels found in normal humans range lrom 0.5 to 10 pg/ml depending 
on the state 01 hydration. Under pathophysiologioal oondilions like hypotensive hemorrhage 
and surgical procedures plasma AVP levels can increase to levels ranging from 50 to 600 
pg/m 132.49,so,61 ,;;2,53,64,6-5,58. 
AVP is a short aoling hormone with a plasma hall-life of 17-35 minutes". The major 
part 01 AVP is removed lrom the plasma through renal seoretion and degradation. A minor 
part is cleared from plasma in the intestine and Iiver68, 
1.1.3 Vasopressin reoeptors. 
Like most hormones AVP exerts its actions through stimulation of selective 
receptors69,60. From studies using different vasopressin analogues, two types of AVP 
receptors have been identified. According to the nomenclature proposed by Michell et al,61, 
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they were called the V,- and the V2-receptor. Stimulation of the Vi-receptor induces 
phosphatidylinositol turnover and a rise in oytosolic oalcium61, 73,62,63.64. V2-receptor 
stimulation activates adenyl ate oyclase resulting in a rise in intracellular 3'-5'-adenosine 
mono phosphate (c-AMP)"'''''', 
Some examples 01 the variety 01 biologic effects 01 AVP that can be demonstrated 
in in vitro and in in vivo experiments are; vasoconstriction67,6!\,69)0, induction of platelet 
aggregation7', stimulation of glycogenolysis in hepatocytes6', 73,64, inhibition of renin 
secretion from juxtaglomerular cells72,73,74, the antidiuretic effece,66, stimulation of the 
release of Adrenocorticotrophic Hormone (ACTH) from the anterior pituitary76,76,77 and 
elevation 01 plasma levels 01 clotting laclor VIII ( FVIII:C ), von Willebrand lactor (vWF:ag) 
and tissue-type plasminogen activator (t-PA:ag)'''', From pharmacological experiments the 
type of receptor related to some of these effects is well defined. Vasoconstriction, platelet 
aggregation, glycogenolysis in hepatocytes, stimUlation of prostaglandin production and 
inhibition of renin seoretion by AVP, were demonstrated to be Vi-receptor relatecf6,6', 
73,80,81,82,83,84,85,86,67,68,89,90,91,92,93,94,95,96 
The antidiuretio effect is caused through stimulation of V 2-receptors located on the 
tubular cells of the renal collecting ducts66,97, The inorease in intracellular c-AMP, following 
V2-receptor stimulation, in its turn oauses an increase in permeability for water of the apical 
membrane of these tubular cells resulting in the antidiuretic effecf9,66,98. An exception to 
the sharp distinction between V1- and V2-receptors are the AVP-receptors involved in the 
corticotropin release hormone like effeot of AVP in the anterior pituitary77, Based on work 
with several AVP-antagonists, Jard suggested these receptors to be called V 1b-
receptors99,I00, 
In a variety of tissues, the presenoe of AVP-receptors can been demonstrated by 
using pharmacological and autoradiography techniques (table 1). V,-receptors were lound 
on a great variety of cells, ranging from thrombooytes and vascular smooth muscle cells to 
adrenal cortical cells (table 1)61,73.82,84,86,101, Up to now, V2-receptors have only been found 
on tubular cells of renal collecting ducts and in several locations in the central nervous 
system91,102,103. 
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Table 1. Biological effects of vasopressin. 
Cell type Effect Receptor 
vascular smooth mUscle vasocontriction V, 
renal tubular cells antidluresls V, 
blood platelets aggregation V, 
hepalocytes glycogenolysis V, 
juxtaglomerular cells inhibition of renin secretion V, 
renal mesangial cells PG E2-producilon V, 
adrenal cortical cells glucocorticoid production V, 
anterior pituitary ACTH-release V, 
endothelium FVUI:C release ? 
vWF:ag release ? 
t-PA release ? 
brain memory fUnction ? 
1.1.4 Cardiovascular effects of vasopressin. 
AVP is one of the most potent vasoconstriotor hormones known. In in vitro 
experiments, it was demonstrated to be more potent than noradrenalin and angiotensin II 
on molecular base67• Yet, its funotion in blood pressure regulation and its possible role in 
the pathogenesis of hypertension remains subjeot of debate66,IQ4,105,106,I07 
It was Howell2 who desoribed a fall in heart rate together with the increase in blood 
pressure, after the initial report of the effect on blood pressure of intravenous 
administration of crude pituitary extract in dogs. The following years it was observed from a 
variety of experiments that the hemodynamic effect 01 AVP inlusion in animals is strongly 
affected by several faolors, like the species used in the experiment and the preparation of 
the animal before AVP infusion, For example rats show a pressor response to muoh lower 
doses of AVP, on weight base, than dogs and the administration of anaesthetic or ganglion 
~Iooking drugs before AVP infusion can result in a muoh greater blood pressure 
responseM6• As AVP measurements, could only be performed by using bioassays, before 
the introduction of sensitive radioimmuno assays, the rat blood pressure assay, was the 
only offioially recognized method for standardization of vasopressin preparations, and was 
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performed according to very strict protocols. 
As mentioned above, the increase in blood pressure after AVP administration in 
intact animals, but also in man, is accompanied by a fall in heart rate and cardiac 
output56,I01.1,I09,llO,II1,112,113. As these eHects on the heart rate and cardiac output, in animals, 
can be abolished by culling the vagi surgically or chemically by either ganglion blocking 
agents or atropine, they are the result of baroreflex mediated counterregulation. When the 
baroreflex is blocked by either procedure, the effect of AVP on blood pressure becomes 
more pronounced5,56,114,115,116. The fall in heart rate is much greater in relation to the 
increase in blood pressure after AVP infusion than after administration of other 
vasopressor agents like angiotensin II or noradrenalin l17,118, From these and other 
observations, can be concluded that AVP itself has an effect on the gain of the 
barorefiex24,56,119. 
Although the antidiuretic effect of posterior pituitary preparations in man was well 
established by many investigators after the initial report of Von den Velden in 19133 , the 
pressor effect of AVP in hUmans Was firstly demonstrated by Wagner and Braunwald in 
195612°, In an experiment in which they administered "vasopressin" intravenously to three 
patients with primary autonomic insufficiency they observed a rise in arterial blood 
pressure together with an increase in peripheral resistance without any changes in cardiac 
output or heart rate. When Mohring et al109 administered AVP to humans by continuous 
infusion, the same relation between a small increase in blood pressure and a marked fall 
in heart rate, as found in animal experiments, was observed at infusion rates resulting in 
plasma AVP levels of ±450 pmol!l. They also found in three patients with autonomic 
insufficiency. that infusion of small amounts of AVP resulling in plasma AVP levels slightly 
above the normal range, markedly increased blood pressure. Later, Simpson et al121 
demonstrated AVP to have marked effects on peripheral resistance and cardiac output, at 
plasma concentrations, that had no effect on blood pressure. From these experiments, can 
be concluded that also in humans, AVP is a potent vasoconstrictor, whose effects on blood 
pressure are largely counter balanced by the baroreflex. 
In medical practice, i.v. administration of AVP is used in the treatment of gastro-
intestinal bleeding57,122. In this situation however, AVP is not merely used for its effect on 
blood pressure, but rather for its effect on the portal venous pressure, which is reduced as 
a result of a diminished splanchnic arterial blood floW l23,124. Unfortunately, the therapeutio 
use of AVP, in this setting, is frequently limited because of abdominal discomfort and 
angina pectoris, experienced by the patient. Another side effect frequently seen is a 
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pronounced vasoconstriction of the peripheral arteries, resulting in cold painful digits 110, 
In several studies, marked differences in vasoconstrictor effect of AVP in different 
vascular beds were observed125,126,127,128, In dogs the blood flow reduotion by AVP is most 
pronounced in the splanohnio bed, skeletal muscle, oompaot bone and skin6Ei ,127,129. 
Although AVP has long been thought to cause coronary vasoconstriction the reduction in 
coronary perfusion is most likely the result of the decrease in heart rate and left ventrioular 
work6Ei,130,131, Total renal perfusion, has been reported not to be affected by AVpI25,127,130. 
However, other investigators found a shift in renal blood flow from outer cortex to inner 
oortexI32,133,I34. Not only regional differences in vasoconstriotor effect of AVP have been 
found, even an endothelium dependent vasodilator action has been demonstrated, in vitro, 
in the basilar artery of dogs!&>. 
Extensive research has been done to eluoidate a possible role of AVP in the 
pathogenesis of hypertension. Up to now, only conflicting results have been obtained"·I04. 
AVP was demonstrated to promote the development of hypertension in DOCA salt 
hypertensive ratsl36,137,138,139, and AVP VI-receptor antagonists were demonstrated to 
reduce blood pressure in spontaneously hypertensive rats!<W. In humans, plasma AVP 
levels were found not to be elevated in essential hypertension56,141. However, 
administration of a VI-antagonist to hypertensive patients with end-stage renal 
insuffioiency, has been demonstrated to cause a reduction in blood pressure142, In patients 
with matignant hypertension elevated plasma AVP levels can be found, but patients with 
inappropriate ADH secretion (SIADH), who have chronicalty elevated plasma AVP levels, 
are usually not hypertensivel43,I44, Although the preoise role of AVP in blood pressure 
regUlation in man is not olear, most evidence points at a function in short term blood 
pressure regulalion56,105, 
1.2.1 1-Desamlno-S-D-arglnlne vasopressin (DDAVP). 
Du Vigneaud et al. were the first to show that alterations in the aminoaoid 
composition of AVP, result in major ohanges in biologioal activity and speoifioity l45, Since 
then, a large number of AVP analogs have been synthesized, with different agonist and 
antagonist actions on both V1- and V2-reoeptors 146,147,148,149,IW,151,152,H;3,164.155.156, 
1-Desamino-8-D-arginine vasopressin (DDAVP), first synthesized in 1965, is a 
vasopressin analog with specifio antidiuretio properties and virtually no vasopressor 
effects l46,167, The relative affinity of DDAVP for V2-receptors is 1.6 times that of AVP, where 
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its relative affinity for Y,-receptors is only 0.009 times that of AYPI4'. The enhanced 
antidiuretio effect is most likely due to the deamination of hemicysteine in position 1. 
Substitution of the D~isomer of arginine for L-arginine at position 8 resulted in the loss of 
vasopressor action 167, 158,158, Most likely this sUbstitution also accounts for the prolongation 
of the plasma halflile of AYP as compared to AYP, as a result of impaired enzymatic 
cleavage of the molecule at the proline-arginine junctionl~. 
Nowadays, DDAYP is the drug of lirst choice in the treatment of central diabetes 
insipidus for several reasons. First of all the loss of vasopressor aotion considerably 
reduced the amount of side-effeots as compared to treatment with AVP. Furthermore, its 
prolonged activity and the possibility of intra-nasal administration, made its use much more 
convenient to the patient145,169,lSO,161,162,163, 
1.2.2 DDAYP; effects on ffbrlnolysls and blood clotting. 
Several vasoactive drugs, like AVP, adrenaline, and nicotinio acid, are known to 
increase plasma levels of tissue-type plasminogen activator (t-PA:ag) and clotting factor 
YIII (FYIII:C) in man"''''. A possible explanation of the phenomenon that such diverse 
drugs can elicit the same effect, is that the release 01 both FYIII:C and t-PA:ag are caused 
by their effect on vasoular motility. 80th Mannucci at al.78 and Cash at al. '65, more or less 
independent of each other, evaluated this hypothesis in healthy volunteers, by infusion of 
ODAVP, which at that time was considered to have no vascular effects. In both 
experiments, intravenous administration of DDAVP resulted in an even greater rise of 
plasma levels of t-PA:ag than that observed after AVP infu5ion18.165,168, In Mannuccits 
experiment this phenomenon was also observed considering FVIII:C and vWF:ag78• Not 
only in healthy volunteers, but also in patients with mild to moderate hemophilia A and von 
Willebrand's disease, DDAVP oan oause a rise in FVIII:C and vWF:ag '67,'68,'69,170. As a 
result of this line of research, nowadays, DDAYP is widely used in the treatment of these 
patients, in order to stop and prevent hemorrhage, without the need for use of 
transfusions 171, 172,173, 
Not, only in patients with hemophilia or von Willebrand's disease but also in a 
variety 01 other clotting disorders, both inherited and acquired, DDAYP proved to be very 
effeotive in improving hemostasisl45,174,175,176,m,178,179,180,181,182, DDAVP oan even be used in 
patients without prior olotting disorders in order to reduoe intraoperative blood loss during 
major surgeryl83. 
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1.2.3 Hemodynamic effects of DDAVP 
The initial reports on the effects of DDAVP on blood clolling and fibrinolysis claimed 
that no side eHects of intravenous administration of DDAVP were observed78,165,166. 
However, shortly afterwards faoial flushing and mild palpitations were reported as side-
effects of the use of DDAVP'67,184. Further evaluation of these side-effects revealed that 
intravenous administration of 0.3-0.4 glkg DDAVP in healthy volunteers results in facial 
flushing, a lowering of diastolic blood pressure without any effect on systolic blood 
pressure, and a marked increase in heart raI6 '85,I86,187. These hemodynamio changes were 
accompanied by a marked rise in plasma renin and plasma noradrenalin levels l86, 188,187, So 
it seems to be that DDAVP oan cause vasodilatation. 
In the original paper, in whioh these effects were described, it was suggested that 
DDAVP possibly acted as an antagonist of endogenous AVP at the V,-receptor, as their 
hemodynamio effects are directly opposite of each other l86• 186, However this would imply 
that the effects of DDAVP on FVIII:C, vWF:ag and t-PA:ag are based on another 
mechanism than the hemodynamic effects, as they are similar to the effects of AVP. 
1.3 Aim of the thesis. 
Our interest in DDAVP was raised after the reports on the side effects observed 
after intravenous administration of O.3~O.4~glkg DDAVP, used in order to increase plasma 
levels of FVIII:C and vWF:ag. Initially, the facial flushing and palpitations of which the 
patients complained were considered to be unpleasant but merely unimportant. In our view 
however, it opened a new approach to investigate the mechanism by which AVP is 
involved in the regulation of blood pressure in man. 
As discussed in section 1.2.3, the first question that arose was whether it is V1-
receptor antagonism or V2-receptor agonism that invoked the hemodynamic effects of 
DDAVP. Either answer to this question would open new possibilities in AVP research. If 
DDAVP would turn out to be a V,-receptor antagonist of endogenous AVP, then it might be 
possible to use DDAVP in order to investigate the possible role of AVP in the pathogenesis 
of hypertension in man. When it is V2-receptor stimulation that causes the hemodynamic 
effects of DDAVP, new questions about this receptor would rise. As V2-receptors have only 
been demonstrated to be present in the kidney, the localization of the V,-receptor that 
causes the hemodynamic changes after DDAVP infusion would need to be clarified. 
Furthermore, the question would arise whether V2-receptor stimulation by AVP occurs 
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under physiologic and pathophysiologic conditions, and whether this is of importance to the 
hemodynamio effeols of AVP in man. 
Also Ihe mechanism by whioh DDAVP invokes Ihe ohanges in blood pressure and 
heart rate needs to be elucidated. Most likely the decrease in diastolio blood pressure and 
the increase in heart rate are the result of vasodilatation,' up to now this is insuHiciently 
SUbstantiated in man. 
Wilh Ihis in mind we sludied bolh Ihe hemodynamio effeols and Ihe effeols on 
FVIII:C, vWF:ag and I-PA:ag of inlravenous adminislralion of DDAVP in man. Our objeolive 
was, to eluoidate the mechanism by whioh ODAVP exerts these effects, and to evaluate at 
what plasma levels of DDAVP these effects can be demonstrated. This thesis oontains the 
results of these studies. 
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Chapter two 
VASCULAR EFFECTS OF 1·DESAMINO·8·D·ARGININE VASOPRESSIN (DDAVP) IN 
HEALTHY VOLUNTEERS 
29 
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2.1 Summary 
Arginine vasopressin (AVP) causes antidiuresis via stimulation of AVP V2-receptors 
on renal tubular cells, and vasoconstriotion via extrarenal and intrarenal vascular V,-
receptors. There is evidenoe to suggest that AVP also stimulates vascular V2-receptors. 
Data on vascular effects in normal subjects that are possibly mediated by V 2-receptors are 
scarce. 
We studied the effects of the seleotive vasopressin V2-receptor agonist 1-desamino-
8-D-arginine vasopressin (DDAVP) on blood pressure, heart rate and the plasma levels of 
renin, clotting factor VIII (FVIII:C), von Willebrand factor (vWF:ag), tissue-type plasminogen 
activator activity (t-PA:ag), tissue-type plasminogen activator antigen (t-PA:ag), 
plasminogen activator inhibitor (PAl), and noradrenaline, adrenaline, and dopamine in 
heallhy volunteers. Twelve subjects were randomly assigned to DDAVP (400 ng/kg Lv. in 
10 minutes) or solvent. ODAVP caused a fall in diastolio blood pressure and a rise in heart 
rate while systolic pressure was unchanged. The rise in heart rate was associated with 
increments in plasma renin and noradrenaline. These responses are propably baroreflex-
mediated. In view of the small drop in blood pressure however, the rise in heart rale after 
DDAVP was disproportionally high. Adrenaline and dopamine did not change. FVIII:C and 
vWF:ag rose as did t-PA:ag and t-PA:act. The rise of plasma t-PA:act was associated with 
the disappearance of PAJ. It is unlikely that the infusion of 400 nglkg DDAVP resulted in 
plasma levels high enough to cause an antagonistio effect at the V1-receptor. We conclude' 
that the responses described here are oaused by V 2-receptor stimulation. The 
disproportionate rise in heart rale after ODAVP may be related to central V2-receptor 
stimulation, as has been described in animals, 
2.2 Introduction 
Arginine-vasopressin (AVP) is a peptide hormone with a number of biologioal 
effects. These effects are brought about through stimulation of two different types of 
receptorsl. Binding of AVP to the V1-receptor causes a rise In oytosolio calcium and an 
increase in phosphatidylinositol turnover. Aotivation of vasoular V1-receptor leads, through 
this pathway, to vasoconstriction'. The antidiuretic effect of AVP is caused by stimulation of 
the V,-receptor looated on the tubular cells of the renal collecting ducts. Binding of AVP to 
this receptor is followed by activation of adenylate-oyolase, whioh causes an inorease in 
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intraoellular 3!-5!adenosine mono phosphate (o-AMPf. 
l-Desamino-S-D-arginine vasopressin (DDAVP) is a synlhetic analog of AVP which 
is virtually devoid of vasopressor aotivity but has retained the antidiuretio properties of 
AVp4". For Ihis reason DDAVP is widely used as a subslilule for AVP in palienls wilh 
oentral diabetes insipidus6,7. 
Mannuooi et al.8 and Cash et a1.9,10 reported that intravenous (Lv.) administration of 
a high dose of DDAVP in healthy volunteers, oaused a rise in the plasma levels of tissue-
Iype plasminogen aclivalor (I-PA), cloHing faclor VIII (FVIII:C), and von Willebrand faclor 
(vWF:ag). Because of ils effecls on FVIII:C and vWF:ag, DDAVP is used in patienls wilh 
haemophilia A and von Willebrand's disease, 10 slop or prevenl bleeding". In Ihis selling, 
Lv. administration of DDAVP oaused faoial flushing and palpitations as side_effeotsI2,13. 
These effects are propably related to a vasodilator action of DDAVp I4,15. 
The present study was oarried out to quantify the effeots of i.v. administration of 
DDAVP on blood pressure, heart rale, and Ihe plasma levels of renin, FVIII:C, vWF:ag, t-
PA, and noradrenaline, adrenaline, and dopamine in healthy volunteers in a double blind 
placebo-conlrolled sludy design. 
2.3 Melhods 
2.3.1 SubJecls 
Twelve male healthy volunleers (aged 23-55 years) from Ihe medical slaff of our 
departmenl participaled in the sludy. They were randomly assigned 10 eilher DDAVP or 
placebo in a double blind fashion. They had nol used any kind of medication for at leasl 
four weeks prior to the study. Informed consent was obtained from all partioipants. The 
study protoool waS approved by the medical ethios oommittee of our hospital. 
2.3.2 DDAVP·tests 
At the beginning of the test, a Teflon oannula was inserted into the anteoubital vein 
on eaoh side. One cannula was used for infusion, the other to obtain blood samples. 
After one hour of supine bedresl, DDAVP or placebo was infused in exaclly 10 
minules. Before each lest, DDAVP (Mimin, Ferring, Malmo, Sweden) or placebo (DDAVP 
solvenl, provided by Ferring, Malmo, Sweden) were diluled in 100 ml saline. The final 
DDAVP solution conlained 400 ng DDAVP per kg body weight. 
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Blood pressure and heart rate were recorded at 5 minute intervals, using an 
automatio osoillometrio devioe (Acoulor, Oatasoope Corp., Paramus, N.J.). Blood samples 
were drawn 10 minutes before the infusion and at 0, 10, 20, 30, and 60 minutes. 
2.3.3. Assays 
Blood samples were oentrifuged for 10 minutes at 5000 rpm. The supernatant was 
deoanted and snap frozen. Plasma was stored at -70°C until assay. The following 
substanoes were assayed: renin, noradrenaline, adrenaline, dopamine, FVIII:C, vWF:ag, 
tissue type plasminogen aotivator antigen (t-PA:ag), tissue-type plasminogen activator 
aclivily (I-PA:acl), and plasminogen activalor inhibilor (PAl). 
Renin was measured by its ability to oleave angiotensin I from sheep renin 
substrate'S. Noradrenaline was measured by high performanoe liquid chromatography with 
electroohemioal detection17• Factor VIII:C was measured in a one stage assay18, and 
vWF:ag was determined by rooket immunoeleotrophoresis. T-PA:ag was measured with an 
enzyme-immunoassay, using a kil (Immulyse IPA) purchased from Biopool (Umea, 
Sweden). T-PA:aot was assayed in euglobulin fractions of plasma using a ohromogenic 
sUbstrate'9. PAl was determined using a titration method whioh measures remaining free 1-
PA after Ihe addition of I-PA 10 diluled plasma". 
2.3.4.Statlstlcal analysis 
Baseline values of the data in both groups were compared using a Student-t test. 
The results of the infusion of plaoebo and DDAVP were oompared in an analysis of 
varianoe for repeated measurements in the same subJeot. Plasma renin was analysed after 
logarithmio transformation. 
2.4 Results 
Baseline values of blood pressure, and heart rate, and the plasma levels of renin, 
noradrenaline, adrenaline, dopamine, FVIII:C, vWF:ag, I-PA:acl, I-PA:ag, and PAl were nol 
diNerenl belween Ihe DDAVP and placebo groups. 
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Figure 1. Effecls of DDAVP (400 nglkg I.v. In 10 mlnules)(m- - -m) 
and placebo (0 __ ) on blood pressure and heart rate. 
* p < 0.05, .** P < 0.001. 
All volunteers receiving DDAVP experienced facial flushing 2 - 3 minutes after the 
beginning of the infusion. In none of the controls facial flushing was noted. In the placebo 
group heart rate and blood pressure did not change (Fig. I). The plasma levels of renin. 
noradrenaline, adrenaline, dopamine, FVIII:C, vWF:ag .. t-PA:ag, t-PA:act, and PAl also did 
nol change (Fig.2 - 5). DDAVP caused a 31% (18 - 44)(mean, 95% confidence interval, p 
< 0.001) increase in heart rate togelher with a 14% (2-20, p < 0.05) reduction in diastolic 
blood pressure (Fig. I). Systolic blood pressure did not change (Fig. I). 
Plasma renin rose rapidly to 130% (61 - 200, P < 0.001) above baseline at the end 
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and placebo (e--'-8) on plasma renin. ** p < 0.001. 
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of Ihe DDAVP infusion (10 minules), and rose further 10 a maximum al 20 minules (Fig.2). 
Plasma noradrenaline followed Ihe same pallern (Fig.3). Adrenaline and dopamine did nol 
change. FVIII:C and vWF:ag rose more gradually than renin and noradrenaline. vWF:ag 
rose 10668% (125· 1212, p<0.05), and FVIII:C rose 10 85% (7·163, p<O.001) above 
baseline al60 minules (Fig.4). T·PA:ag rose 10 173% (1 ·348, P < 0.001) above baseline 
al 20 minules (Fig.5). 
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Figure 4. Effecls of DDAVP (400 ng!J<g i.v. in 10 mlnutesHm- - ·m) 
and placebo (e-------e) on plasma FVIiI:C and vWF:ag. 
"* p < 0.05, .** P < 0.001. 
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Prior to DDAVP infusion, t-PA:act was hardly detectable in plasma. In all subjects 
receiving DDAVP, t-PA:act rose, whereas at the same time PAl practically disappeared 
from plasma (Fig.5). At the end of the observation period (60 minutes) t-PA:ag and t-
PA:act began to return to baseline and at the same time PAl reappeared. 
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2.5 Discussion 
In this study we conlirmed the effects of DDAVP in healthy volunteers reported by 
others1S,21, As compared to the studies of Mannucci et al.22 and Williams at al.16 this study 
provides more detailed data on the haemodynamio responses to DDAVP. These 
responses are likely to be caused by a vasodilator action of DDAVP. The inorements in 
heart rate and in plasma renin and noradrenaline are propably caused by baroreflex 
stimulation. The increase in heart rate after DDAVP appears to be greater than with other 
vasodilators, considering the small drop in blood pressure. Inorements in heart rale as big 
as we observed have also been reported with other vasodilators, but only when the 
changes in blood pressure were more marked than with DDAVP22,2;),24, Considering the 
baroreflex as a closed loop negative feedback system, the disproportionate effect of 
DDAVP can be characterised as an increase in the gain of the baroreflex, A similar action 
on the baroreflex has been attributed to AVp25,26,27,28,29. Infusion of AVP, which acts as a 
potent vasoconstrictor, causes little rise in blood pressure, but, in spite of this small effect 
on pressure, the heart rate falis markedly. AVP and DDAVP may therefore affeot the 
baroreflex through a similar mechanism. This possibility was addressed by Unger et al.3O 
who found that intravenous infusion of AVP in rats caused an increase in the gain of the 
baroreflex through simulation of V2~receptors in the brain. 
The increase in plasma renin we observed, most likely reflects renal sympathetic 
stimulation3!. Renal vasodilatation may also playa role. A direct V2-receptor-mediated 
increase in renin secretion is unlikely since only VI-receptors seem to be present on 
juxtaglomerular cells3 • 
The changes in FVIII:C and vWF:ag we observed, are similar to those described by 
others3 2,33, The time course of these changes differed from the time course of renin and 
noradrenaline ohanges. This may indioate that the regulation of the endothelial release of 
FVIII:C and vWF:ag is essentially different from the regulation of renin and noradrenaline 
release. However differences in plasma half life can also contribute to the observed 
changes over time, 
Since t-PA binds to PAI2o,34, the increase in t-PA:act in plasma underestimates the 
total amount of aotive t-PA released from endothelium. The decrease In t-PA:aot at the end 
of the experiment appears to be due to a decrease in t-PA:ag as well as the reappearance 
of PAl. 
Oerkx et a/.14 found that DDAVP at concentrations in the order of micrograms per 
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ml was an antagonist AVP at the V1-receptor of blood platelets and juxtaglomerular cells. 
Considering the distribution volume of DDAVP35,36 the amount of DDAVP we used in this 
study it too small to give such high levels. It is therefore unlikely that antagonism of 
endogenous AVP at the V,-receptor can account for the effects of DDAVP. Thus the 
effects of DDAVP in healthy volunteers we describe here appear to be caused by V2-
receptor stimulation. 
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Chapter three 
1·DESAMINO·8·D·ARGININE VASOPRESSIN (DDAVP) IN PATIENTS WITH 
CONGENITAL NEPHROGENIC DIABETES INSIPIDUS. 
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3.1 Summary 
In healthy subjects, Lv infusion of the seleotive V2R vasopressin receptor agonist 1-
desamino-S-D-arginine vasopressin (DDAVP 400 nglkg in 10 minutes) causes a marked 
increase in heart rate with a slight decrease in diastolio blood pressure. These 
haemodynamic responses are assooiated with inorements in the plasma levels of renin, 
noradrenaline (NA), dolling factor VIII (FVIII:C), von Willebrand factor (vWF:ag), and 
lissue-type plasminogen aclivator (t-PA), and a fall in the plasma level 01 plasminogen 
activator inhibitor (PAl). None of these were observed in three patients with congenital 
nephrogenic diabetes insipidus (NDI), who had a genelic defect of the V,-receptor. Plasma 
AVP levels in these patients were normal Of slightly elevated, which makes it unlikely that 
the lack of DDAVP responsiveness was caused by down-regulation of vasopressin V1-
receptors. In one NOI patient, arginine vasopressin (AVP) was given in incremental doses. 
62.5 - 4000 pglkglmin. The heart rate and blood pressure responses to AVP were normal, 
indicating the absence of an VI-receptor defect. The responses of vWF:ag and t-PA to 
venous occlusion in the patients with NOI were similar to the responses in five healthy 
volunteers, which indicates that in NDI the endothelial release of both vWF:ag and I-PA is 
normal. We conclude that DDAVP causes its effects on heart rate and blood pressure. and 
on the plasma tevels 01 renin, noradrenaline, FVIII:C, vWF:ag, and t-PA through V,-
receptor stimulation. 
3.2 Introduction 
The antidiuretic hormone. arginine vasopressin (AVP). causes its effects through 
stimulation of two dillerent types of receptors'. Michell et al.' postulated that the 
vasopressor action of AVP is mediated through stimulation of the V1-receptor, which 
causes an increase in phosphatidylinositol breakdown and a rise in cytosolic calcium. The 
V2-reoeptor is responsible for the antidiuretio action of AVP. Binding of AVP to the V2-
reoeptor, causes activation of adenylate cyclase which results in a rise in intracellular 3'-
5'adenosine mono phosphate (c-AMP). 
1-Desamino-S-D-arginine vasopressin (DDAVP) is a synthetic analog of AVP, which 
has retained the antidiuretio. but not the vasopressor action of AVP3. Because of these 
properties. DDAVP is used in the treatment of oentral diabetes insipidus4. Intravenous (Lv.) 
administration of DDAVP oauses an increase in plasma levels of clotting factor VIII 5 
(FVIII:C), von Willebrand factor' (vWF:ag) and tissue-type plasminogen activator'·7 (1-
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PA:ag). As t-PA in plasma binds to plasminogen activator inhibitor (PAl)', an increase in 
the plasma level of t-PA will lead to a fall in plasma PAl'. Because of its effects on FVIII:C 
and vWF:ag, OOAVP can be used in patients with haemophilia A or von Willebrand's 
disease to stop or prevent bleedinglO• Initially. only an increase in heart rate and mild facial 
lIushing were reported to be side effects of OOAVP treatment". 
OOAVP (400 ng/kg body weight i.v. in 10 minutes), which is a dose that is also 
used in patients with bleeding disorders, causes a marked increase in heart rate and a 
minor decrease in diastolic blood pressure together with a rise in the plasma levels of renin 
and noradrenalinel2,13. These findings, and the results of in vitro experiments, made Derkx 
et al. 12 suggest that DDAVP may aot as a VI-receptor antagonist. However, in a 
pharmacokinetic study, we found that the doses of OOAVP we used resulted in plasma 
levels three orders of magnitude lower than the DDAVP conoentrations required for V,-
receptor antagonism in vitro9 , 
Congenital nephrogenic diabetes insipidus (NOI) is an X-linked disorder in which 
the renal colleoting tubules are insensitive to stimulation by AVP leading to marked poly-
uria'4. In contrast to central diabetes insipidus, patients with NOI do not respond to 
treatment with AVP or OOAVP. The molecular basis of this disease is a gene1io defect of 
the vasopressin V2-receptor or a defect at the post-receptor level. Kobrinsky et al.15 
reported that i.v. OOAVP in patients with NOI did not result in a rise in the plasma levels of 
FVIII:C and vWF:ag or facial flushing. In our previous work, we found that in NOI not only 
the plasma levels of FVIII:C and vWF:ag, but also blood pressure, heart rate and plasma 
levels of t-PA did not change after OOAVP Lv.9 • These results were later confirmed by 
Siohel et al.'6. 
From Ihese studies it was conoluded that the haemodynamio effects and the 
inoreases in FVIII:C, vWF:ag, and t-PA were caused through V2-reoeptor stimulation9,15,16. 
However, there are several other possible explanations for the absenoe of the effects of 
OOAVP in NO!. First, patients with NOI might have chronioally elevated plasma AVP levels 
leading to down-regulation of Vl~reoeptors. Seoond, it is possible that not only the V2-
reoeptor but also the VI-receptor is not functioning properly in NO!. Third, in NOI the 
release of vWF:ag and t-PA from endothelium might be defective. 
In this study, we investigated the haemodynamio effects of OOAVP, together with 
its effects on blood clotting and fibrinolysis in three patients with NO!. The funotional 
integrity of the vasoular V1-receptor was tested in one of these patients. The release from 
endothelium of vWF:ag and I-PA, in response to venous ooolusion, was studied in normal 
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volunleers and in Ihe palients with NDI. 
3.3 Pattents and methods 
3.3.1 Patients 
Three palients with NDI participated in this study. All three had a lifelong history of 
polyuria and polydipsia. Palients 1 and 2, aged 28 and 30 years, were brothers who both 
suffered several episodes of severe dehydration in childhood resulting in mental 
retardalion. The diagnosis of NDI was established when they were 4 and 6 years old. 
Patient 3, aged 32 years, had several male relatives, who had a daily urine oulput of 15 to 
20 litres. In this palient the diagnosis of NDI was established at an early age, so adequate 
fluid replacement therapy prevented dehydralion in early childhood. 
In all three palients NDI was diagnosed during a water deprivalion test, in which 
they showed a defective urine concentrating ability and an absent rise in urine osmolality 
after the intramusoular administration of AVP. On physioal examination prior to the present 
study, the three patients with NDI did not show any sign of dehydralion. The results of 
urine analysis and serum electrolyte, urea and creatinine concentrations were normal. All 
three patients gave informed consent prior to the study. Beoause patients 1 and 2 were 
mentally retarded, informed consent was also provided by their parents. The study protocol 
was approved by the Medical Ethics Review Committee of our hospital. 
3.3.2 DDAVP·test 
In both arms an Lv. cannula was inserted in the antecubital vein, of whioh one was 
used for DDAVP infusion and the other for the collection of blood, at the beginning of the 
experiment. After one hour of supine bedrest, 400 ng/kg body weight of DDAVP (Ferring, 
Malmo, Sweden) dissolved in 100 ml saline, was infused in 10 minutes. Blood samples 
were collected at ·10, 0, 10,20,30, and 60 minutes from the beginning of the DDAVP 
infusion. Blood pressure and heart rate were measured at 5-minute intervals. In aU blood 
samples osmolality, plasma renin, noradrenaline, FVIII:C, vWF:ag, t-PA antigen (t-PA:ag), 
and plasminogen activator inhibitor (PAl) were measured. AVP was measured in the blood 
samples collected prior to the DDAVP infusion. The data from the DDAVP·tests in the 
three patients with NDI were compared with the effects of DDAVP in normal volunteers 
which have been described previouslyl2,l7. 
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3.3.3 AVP·lnfusion 
In patient 3 the effects of AVP infusion on heart rate and blood pressure were 
studied. After one hour of bed rest, AVP (Ferring, Malmo, Sweden) was infused through an 
Lv. cannula. Every 30 minutes, the rate of infusion was doubled from 62.5 pglkg/min AVP 
up to 4000 pg/kg/min AVP. Heart rate and blood pressure were measured at 5 minute 
intervals. All heart rate and blood pressure measurements, in both the OOAVP test and the 
AVP infusion, were performed using an automatio device ( Accular I, Datascope Corp., 
Paramus, NJ}'8, 
3.3.4 Venous occlusion test 
The three patients with NOI and five normal male volunteers (aged 25 . 41 years) 
were subjected to a venous occlusion test. After introduction of a teflon oannula into the 
antecubital vein, a manometer cuff was wrapped around the upper arm. After 30 minutes 
of resting, the culf was inflated to 100 mm Hg for a duration of 15 minutes. Blood was 
drawn from the cannula Just before inflation, and just before deflation of the culf. The blood 
samples were assayed for vWF:ag, t~PA:ag, and PAL Cannulation of the cubital vein of the 
arm subjected to venous occlusion did not give rise to the development of haematomas in 
any of the subjects. 
3.3.5 Assays 
Renin was measured by its ability to cleave angiotensin I from sheep renin 
substrate19. Noradrenaline was measured by high performance liquid chromatography20. 
Factor VIII:C was measured in a one stage assay21 and vWF:ag was determined by rocket 
immunoelectrophoresis. T-PA:ag was measured with an enzyme-immunoassay, using a kit 
(Immulyse tPA) purchased from Biopool (Umea, Sweden). PAl was determined using a 
titration method whieh measures remaining free t-PA after the addition of t-PA to diluted 
plasma22. AVP was measured by radioimmunoassay (Inestar, Stillwater, Minnesota, 
U.S.A.), after extraction from plasma using a Sep·Pak C·18 column. The lower limit of 
detection was 2 pg/ml. The recovery of AVP added to AVP free plasma was 95%. 
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3.4 Results 
3.4.1 DDAVP·test 
The effects of DDAVP in both the normal volunteers and the three patients with 
NOI, on blood pressure, heart rate and the plasma levels of renin, noradrenaline, FVIII:C, 
vWF:ag, t·PA:ag, and PAl are depleted in Figs. 1-4''''. To compare the effects of DDAVP 
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Figure 1. Effect of DDAVP (400 nglkg i.v. in 10 minutes) on blood 
pressure and heart rale in paUents 1 (e--------8), 2 (B- - -a), and 
3 (.6.- . . - . . ..6.) with congenital nephrogenic diabetes insipidus, and 
6 normal volunteers. The dotted fine and the shaded area represent 
the geometric mean ± sd of the dala from the volunteers12. 
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Figure 2. Effect of DDAVP (400 nglkg i.v. In 10 mInutes) on the 
plasma levels of renin and noradrenaline In patients 1 (0_), 
2 (.- - -a), and 3 (A-. ,-, .... ) with congenital nephrogenic 
diabetes insipidus, and 6 normal volunteers. The dotted line and the 
shaded area represent the geometrio mean ± sd of the data from the 
volunteers12, 
in patients with NOI with those in the normal volunteers all data were expressed as their 
percentage of baseline values (I = 0 min). The geometric mean and 95 % confidence 
intervals of these effects in the normal volunteers are given in Tables 1 and 2, and are 
compared with the effects in the patients. 
Belore the administration of OOAVP, heart rate and blood pressure had stabilized in 
the three patients with NOI (Table 1), indioating that they had reaohed basal oonditions. 
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Figure 3. Effect of DDAVP C400 ngA<g I.v. In 10 minutes) on the 
plasma levels of clotting factor VIII (FVIII:C) and von Wlllebrand 
factor CvWF:ag) in patients 1 ce __ ). 2 ca· . ·a). and 3 
(..&.- .. - ...... ) with congenital nephrogenic diabetes insipidus, and 6 
normal volunteers. The dotted line and the shaded area represent 
the geometric mean ± sd of the data from the volunteers17, 
OOAVP inlusion had no effect on blood pressure in Ihe NOI patienls and caused a slight 
decrease in diastolio blood pressure in the healthy volunteers. The marked increase in 
heart rale in Ihe normal volunleers was absenl in Ihe patienls with NOI (Table 1). After 
OOAVP Ihe plasma levels 01 renin. noradrenaline. FVIII:C. vWF:ag, and l·pA:ag showed a 
considerable increase in the normal volunteers, whereas PAl deoreased. These effects 
were not observed in Ihe patienls with NOI (Tables 1 and 2). 
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Figure 4. Effect of DDAVP (400 ngJkg Lv. in 10 minutes) on the 
plasma levels of tissue-type plasminogen activator antigen (t-PA:ag) 
and plasminogen activator inhibitor in patients 1 (e __ ), 
2 (B- - -B). and 3 ( .... - .. - . . .A.) with congenital nephrogenic 
diabetes insipidus, and 6 normal volunteers. The dotted tine and the 
shaded area represent the geometric mean ± sd of the data from the 
volunteers17• 
3.4.2 AVP assay 
Normal values of plasma AVP in our laboratory. in 16 normal subjects (aged 18-48 years). 
ranged Irom 2 - 6 pg/ml. The plasma levels of AVP in patients 1 (11 pg/ml) and 2 (14 
pg/ml) were slightly above normal. Plasma AVP in patient 3 ( 3 pgfml) was within the 
normal range. 
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Table 1. Effect of DDAVP in 6 normal volunteers and 3 patients with NDI. 
time (min) -10 0 10 20 
Systolic blood pressure 
volunteers 100 100 97 99 
(92-109) (83-112) (91-108) 
patient 1 101 100 93 95 
patient 2 105 100 103 109 
patient 3 101 100 102 108 
Diastolic blood pressure 
volunteers 102 100 86 86 
(81-129) (66-111) (74-99) 
patient 1 99 100 86 90 
patient 2 113 100 114 117 
patient 3 94 100 99 103 
Heart rate 
volunteers 98 100 136 124 
(81-118) (113-163) (102-150) 
patient 1 98 100 101 * 98' 
patient 2 113 100 108' 113 
patient 3 95 100 97' 102 
---" 
Plasma renin 
volunteers 110 100 271 323 
(99-122) (153-480) (248-420) 
patient 1 100 100 90" 96"· 
patient 2 127 100 102' 106'" 
patient 3 119 100 110* 132"* 
Plasma noradrenaline 
volunteers 98 100 179 185 
(84-113) (147-218) (127-269) 
patient 1 108 100 109" iDS' 
patient 2 110 100 100" 97' 
patient 3 102 100 110" 112* 
Data presented as percentage of the baseline value (t= 0). The geometric mean and the 95% 
confidence Interval are given for the normal volUnteers. * p < 0.05, H P < 0.01, , .. P < 0.001. 
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Table 2 Effects of OOAVP in 6 normal volunteers and 3 patients with NOt. 
time (min) -10 0 30 60 
~~~,-""~"-"---"-,.--,----~~-"-~-"-,-,-,-~-
FVIII:C 
volunteers 98 100 178 181 
(90-107) (129-247) (120-273) 
patient 1 94 100 101' 95' 
patient 2 97 100 93"" 95' 
patient 3 105 100 52'" 49'" 
vWF:ag 
volunteers 96 100 471 491 
(60-154) (48-4632) (104-2309) 
patient 1 84 100 96 95' 
patient 2 161 100 102 98' 
patient 3 113 100 86 90' 
t-PA:ag 
volunteers 107 100 327 258 
(91-126) (148-726) (131-508) 
patient 1 105 100 96' 104· 
patient 2 95 100 95' 95' 
patient 3 76 100 105' 86' 
PAl 
volunteers 96 100 26 34 
(80-114) (0-61) (0-105) 
patient 1 81 100 121" 110 
patient 2 100 100 113' 114 
patient 3 82 100 95' 82' 
Data presented as percentage of the baseline value (t= 0). Geometric mean and 95% confidence 
interval are given for the normal volunteers. FVIJI:C; etotting factor Viti, vWF:ag; von Willebrand 
factor, t-PA:ag; tissue-type plasminogen activator antigen, PAl; plasminogen activator inhibitor, 
, p< 0.05, .. P < 0.01, .. , P < 0.001. 
3.4.3 AVP InfUsion 
The infusion of AVP in patient 3 resulted in an inorease in blood pressure and a fall 
. in heart rate, which was first noted at an infusion rate of 500 pg/kg/min (fig.5). At the 
highest infusion rate ( 4000 pglkg/min) both the systolic and diastolic blood pressure 
showed an inorease of maximally 10 mm Hg above baseline. This was accompanied by a 
fall in heart rate to approximately 15 bpm below baseline. At the same time the patient 
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Figure 5. The effect of arginine vasopressin infusion (62.5 - 4000 
pg/kg/mfn) on heart rate and blood pressure in patient 3 with 
congenital nephrogenic diabetes insipIdus. 
noted that his hands were getting cold. After discontinuation of the AVP infusion, both 
heart rate and blood pressure rapidly returned to baseline, and the patient reported that his 
hands were getting warm again. Throughout the whole experiment the patient did not 
experience nausea or precordial pain. 
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3.4.4 Venous occlusion test 
The effects of venous occlusion on the plasma levels of vWF:ag, t-PA:ag and PAl, 
in the three patients with NDI and the normal volunteers, are presented in Table 3. In four 
volunteers and in patients 2 and 3, vWF:ag increased. In one volunteer and in patient 1, 
vWF:ag decreased. In all three patients, and in the volunteers t-PA:ag increased. 
In three normal volunteers, PAl dropped to unmeasurable levels. In two of them PAl 
showed only a minor decrease. In patient 1 PAl did not change whereas PAl increased in 
patients 2 and 3. 
Table 3. Effect of venous occlusion In 5 normal volunteers and 3 patients with NO!. 
vWF:ag t-PA:ag PAl 
(U/ml) (ng/ml) (U/ml) 
before after before after before after 
volunteers 1 0.90 1.25 4.6 11.2 2.63 0 
2 1.12 1.38 6.8 28.4 3.07 2.92 
3 0.63 1.09 3.3 13.3 2.01 0 
4 1.22 1.14 7.3 10.5 4.44 3.84 
5 1.02 1.43 5.5 21.7 5.13 0 
patients 1 1.85 1.52 12.2 16.4 2.54 2.54 
2 1.35 1.86 3.3 11.4 1.34 2.45 
3 0.91 1.53 10.7 16.0 5.90 7.80 
3.5 Discussion 
NDI is the result of a defect of the V2-receptor, either of the receptor itself or at the 
post-receptor level14• Thus the laok of any response to DDAVP we observed in NDI 
indioates that the haemodynamio effects of DDAVP in normal volunteers, and the effeots 
on FVIII:C, vWF:ag, t-PA, and PAl are caused by V,-receptor stimulation"". The possibility 
that the effects of DDAVP in our patients with NDI are absent as a resull of down-
regulation of V1-reoeptors is unlikely since they showed no signs of chronic dehydration 
like renal funotion impairment or an elevation of serum osmolality. Furthermore, the plasma 
AVP levels in these patients were hardly elevated. Apparently the patients with NOI were 
capable to oompensate for their urinary water losses by adequate drinking. 
In order to exclude the possibility that the ellects of high dose OOAVP are the 
result of a V,-receptor antagonistic effect, the functional integrity of the V,-receptor in NOI 
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must be considered. The patient we studied showed a vasoconstrictor response to the 
AVP infusion similar to those observed by Mohring et al." in normal volunteers. Although 
AVP was infused in only one patient with NOI, the increase in blood pressure together with 
the fall in heart rate which rapidly returned to baseline after discontinuation of the infusion, 
can be considered as evidence to conolude that at least in this patient with NOI the V1-
receptor is functioning. 
The disproportionate fall in heart rate, oompared to the increase in blood pressure, 
during AVP infusion, as observed in normal subjects has been attributed to an inorease in 
the gain of the baroreflex oaused by AVp24. Unger et al. 25 found in rats that the eHect of 
AVP on the baroreflex was caused by V2-receptor stimulation. This may explain why our 
NOI patient showed no disproportionate fall in heart rate in response to the V1-reoeptor-
mediated increase in blood pressure during AVP infusion. It also explains why in normal 
individuals the rise in heart rate after OOAVP is disproportionate to the V2-receptor-
mediated vasodilatation. 
The possibility that the endothelial release of vWF:ag and t-PA is impaired in NOI, 
has been addressed by Sichet et al.'" who demonstrated that in NOI the plasma levels of 
both substances rise after adrenaline infusion. In the present study we examined the 
release from endothelium of vWF:ag and t-PA by venous occlusion. In the patients with 
NOI as well as in the normal volunteers, t-PA:ag increased with this manoeuvre. In two of 
the three patients with NOI and four of the five normal volunteers vWF:ag also increased, 
but in one of the patients and in one of the healthy sUbjects plasma levels of vWF:ag felt. 
Although the responses showed some degree of variability, these findings do not support 
that the lack of response of t-PA and vWF:ag to OOAVP in NOI is caused by a more 
general endothelial defect. 
From the data presented in this study we conclude that the effects of Lv. 
administration of OOAVP in normal subjects on heart rate, blood pressure, and the plasma 
levels of renin, noradrenaline, FVIII:C, vWF:ag, and t-PA:ag are the result of V,-receptor 
stimulation. 
It is unlikely that these effects are caused by V I-receptor antagonism because the 
dose of OOAVP is much to low to have such an antagonistio effect9•12• The localization of 
the V,-receptor involved in these effects of OOAVP still has to be elucidated. 
It is also unknown if, under certain pathophysiological oonditions, endogenous AVP may 
cause V2-receptor mediated vasodilatation, an effect that would counteract the 
vasoconstrictor action of AVP. The absenoe of an enhanced blood pressure response to 
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exogenous AVP in our patient with NOI does not support that such a V,-receptor-mediated 
counteracting effeot is of muoh physiologic importance. However this was an observation in 
a single patient, and more studies are needed to address this point. 
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Chapter four: 
VASCULAR EFFECTS OF 1·DESAMINO·8·D·ARGININE VASOPRESSIN (DDAVP) IN 
SUBJECTS WITH ESSENTIAL HYPERTENSION OR AUTONOMIC FAILURE. 
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4.1 Summary 
The extrarenal effects of a single high dose of the V 2-receptor agonist 1-desamino-
8-D-arginine vasopressin (DDAVP, Desmopressin) in subjeots with essential hypertension 
and healthy subjects were compared. In addition, the extrarenal effects of lower doses 
were studied in subJeots with essential hypertension. In eight healthy volunteers DDAVP 
(400 ng.kg i.v. in 10 minutes oaused a slight fall (10, 5 - 15 mm Hg, mean, 95 % 
confidence interval, p < 0.001) in diastolic blood pressure without a change in systolic 
pressure. This was aooompanied by marked inorements in heart rate (26, 15 - 37 bpm, p < 
0.001) and in the plasma levels of renin (220, 132 - 309 %, P < 0.001), noradrenaline (110, 
77 -144 %, P < 0.001) and tissue-type plasminogen aotivator antigen (t-PA:ag)(253, 110-
396 %, p < 0.001). These eflects are oompatible with a vasodilator aotion of DDAVP. In 
eight subjeots with essential hypertension, DDAVP oaused a fall in diastolio pressure (11, 4 
- 17 mm Hg) and systolio pressure as well (13, 8 - 18 mm Hg, p < 0.005 with respect to 
healthy volunteers), The effects on heart rate, plasma renin, noradrenaline and t-PA:ag 
were not diflerent lrom those in healthy volUnteers. Plasma levels of DDAVP were 
measured in 6 SUbjects with essential hypertension. Peak levels after the single high dose 
of DDAVP were 2.85 (1.93-4.22) ng/ml. 
Inoremental infusions of lower doses of DDAVP were given to 10 subjects with 
essential hypertension. Cumulative doses were 12.5, 25, 50, 100, 200, and 400 ng/kg i.v. 
at 15 minute intervals. The first significant effect on blood pressure was observed after a 
oumulative DDAVP dose of 100 ng/kg. After this dose systolic blood pressure fell by 12 (5 
- 20) mm Hg and diastolio pressure by 10 (5 - 15)mm Hg. Heart rate rose by 10 (6 -15) 
bpm with this dose. Renin rose by 31 (11 - 50) % and noradrenaline by 45 (27 - 62) %. 
The first significant rise in t-PA:ag was observed after a cumulative DDAVP dose of 200 
nglkg (134,71 -197 %). 
The same protoool was followed in three patients with orthostatio hypotension due 
to peripheral autonomic neuropathy. Already after a oumulative dose of 25 nglkg, systolic 
blood pressure fell by 16 (15 - 18) mm Hg (median, range) and diastolio pressure with 8 (5 
- 12) mm Hg. Heart rate and noradrenaline did not change, whereas renin rose in two 
patients after the highest cumulative dose of 400 ng/kg. The results in these patients 
support the view that the inorease in renin after DDAVP in healthy subjeots and in SUbjects 
with essential hypertension is oaused by sympathetio stimulation in response to the 
vasodilator aotion of DDAVP. 
The oardiovascular effeots of DDAVP observed with the inoremental infusions 
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suggests that under certain pathologioal oonditions endogenous AVP may oause V2-
receptor~medjated vasodilatation. 
4.2 Introduction 
In hUmans arginine vasopressin (AVP) is the natural antidiuretio hormone. Apart 
from its antidiuretio effect, AVP has also a potent vasoconstrictor aotion. These two effeots 
are mediated through two different types of receptors'. Binding of AVP to the vascular V,-
receptors results in vasoconstriction, through stimulation of the breakdown of 
phosphatidylinositol and an increase in cytosolic oalcium. V2~receptors, looated on renal 
tubular cells, are responsible for the antidiuretio effect. Binding of AVP to this reoeptor 
oauses stimulation of adenylate oyolase and inoreased production of 1'5'adenosine 
monophosphate (c-AMP)'. 
1-0esamino-8-D-arginine vasopressin (desmopressin, OOAVP) is a selective V2-
receptor agonise. In healthy volunteers intravenous administration of a single high dose of 
DDAVP (400 nglkg Lv.) causes a slight fall in blood pressure and marked increases in 
heart rate and in the plasma levels of renin and noradrenaline4,5. These effeots suggest 
that DDAVP has a vasodilator action. In addition to its hemodynamic effects, DDAVP also 
causes the release of clotting factor VIII (FVIII:C), von Willebrand factor (vWF:ag), and 
tissue-type plasminogen activator (t-PA) from endothelium". All these effects of DDAVP 
are mediated by V2-receptors8,9.1O. 
In this study we compared the extrarenal effects of a single high dose of DDAVP 
(400 ngikg i.v.) in subjects with essential hypertension and healthy volunteers, and the 
plasma levels of DDAVP were measured, In order to evaluate whether V 2-receptor 
mediated vasodilatation occurs at plasma DDAVP levels that approximate the levels of 
AVP that can be found under certain pathological conditions with stimulated AVP 
release ll .12, we also studied the hemodynamio effects of lower doses of DDAVP (12.5 
ng/kg to 400 ng/kg Lv.) in sUbjects with essential hypertension and in patients with 
orthostatio hypotension due to autonomio neuropathy. The latter group of patients was 
inoluded in the study beoause it was expected that in the absence of autonomic 
oounterregulatory meohanisms the vasodilator effeot of DDAVP would be more manifest. 
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4.3 Methods 
4.3.1 Subjects 
Eight male apparently healthy volunteers (aged 24-51 years) and eight male 
subjects with essential hypertension (aged 34 - 60) received a single high dose of DDAVP 
(400 ng/kg Lv.). Ten additional male subjects with essential hypertension (aged 32 - 60) 
participated in a study in which the extrarenal effects of lower doses of DDAVP (12.5 - 400 
ng/kg Lv.) were investigated. Urine analysis and serum electrolytes, urea and creatinine in 
the hypertensive subjects were normal. Urinary excretion of vanyllilmandelio aoid was also 
normal. Ultrasound imaging and renography using 99Te-DTPA disclosed no evidence for 
the existence of renovascular hypertension. 
The extrarenal effects of low doses of DDAVP were also investigated in three 
patients with autonomio failure. All three had orthostatio hypotension due to peripheral 
autonomio neuropathy. One patient had primary hereditary amyloidosis, one had 
amyloidosis accompanying multiple myeloma, and one patient had idiopathic peripheral 
autonomic neuropathyl3. 
All participants in this study had not taken any kind of medication for at least two 
weeks prior to the study. The study protocol was approved by the Medical Ethics 
Committee of our hospital. All subjects gave their informed consent. 
4.3.2 Single high dose DDAVP 
One hour before the infusion of OOAVP a teflon cannula was inserted into the 
antecubital vein of the left arm, which was used as a vascular access both for the infusion 
of DDAVP and for blood sampling. After 1 hour of supine bed rest 400 nglkg DDAVP 
(Minrin®, Ferring, Malmo, Sweden) dissolved in 100 ml 0.9 % NaGI was inlused in 10 
minutes. After the infusion the cannula was flushed with 10 ml 0.9 % NaC!. 
Blood pressure and heart rate were recorded at 5 minute intervals, using an 
automatic oscillometric device (Accutorr®, Oatascope Corp, Paramus, NY). Blood samples 
were drawn at -10, 0, 10,20,30, and 60 minutes. 
4.3.3 incrementat low doses of DDAVP 
In 10 subjects with essential hypertension and in 3 patients with autonomic failure 
OOAVP was administered in incremental doses at 15 minute intervals up to a cumulative 
dose of 400 ng/kg Lv. The doses 01 DDAVP were 12.5, 12.5,25,50, 100 and 200 ngikg. A 
teflon cannula which was inserted into the left antecubital vein at the beginning of the 
65 
experiment, was used both for the administration of DDAVP and for btood sampling. The 
first dose was administered after 1 hour of supine bedrest and each dose was infused over 
a period of 1 minute. In the subjects with essential hypertension blood pressure and heart 
rate, which were measured with the automatio oscillometrio device, were recorded at 5 
minute intervals from 60 minutes before the first dose, up to 60 minutes after the final dose 
of DDAVP. In the patients with autonomio failure, blood pressure was oontinuously 
measured in a radial artery via a catheter. The heart rate was derived from the 
continuously recorded electrooardiogram. Blood samples were drawn 15 minutes before 
and immediately prior to eaoh dose as well as 15 and 60 minutes after the last dose. 
4.3.4 Assays 
Plasma renin was measured by its ability to cleave sheep renin substrate14, Plasma 
noradrenaline was measured by high performanoe liquid ohromatography with 
eleotrochemioal deteotion16. t-PA:ag was measured by radioimmunoassay16, DDAVP was 
measured in plasma by radioimmunoassay, using 131 1 labelled DDAVP and a specific 
antibody against DDAVP, both provided by Ferring". The radioimmunoassay of DDAVP 
had a lower limit of deteotion of 1.5 pg/ml, and a oross-reaotivity with AVP of 100%. 
4.3.5 Statlstloat analysis 
The effeots of a single dose of DDAVP in normal volunteers and patients with 
essential hypertension and the effeots of inoremental doses of DDAVP in the hypertensive 
subjects and the patients with autonomio failure were analyzed by using an analysis of 
varianoe for repeated measures in the same subjeots. To identify the lowest dose of 
DDAVP that caused a statistioally signifioant change from baseline a Student Newman 
Keuls test was used. Plasma renin levels were analyzed after logarilhmic transformation of 
data. 
4.4 RESULTS 
4.4.1 Single high dose DDAVP 
80th the normal volunteers and the subjects with essential hypertension 
experienoed faoial flushing 2 - 3 minutes after the beginning of the DDAVP infusion. The 
effects on blood pressure and heart rate are depioted in Fig.1. In the heaflhy volunteers, 
DDAVP oaused a fall in diastolio blood pressure of 10 ( 5 - 15 ) mm Hg from baseline 
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Figure 1. Effect of DDAVP (400 ng/kg Lv. in 10 minutes) on blood 
pressure and heart rate in 8 healthy volunteers (.- ~ ~.), and 8 
subjects with essential hypertension (.-~.). Data presented as 
mean ± sd, * P < 0.05 for difference between groups, 
(mean, 95% confidence interval, p < 0.001 L without any signifioant ohange in systolio 
pressure. Heart rate rose by 26 ( 15 - 37) bpm (p < 0.001). Renin increased by 220 (132-
309) % (p < 0.001), and noradrenaline by 110 (77 - 144) % (p < 0.001)(Fig.2). Plasma t-
PA:ag rose by 253 (110 - 396) % (p < 0.001). 
In the subjects with essential hypertension the diastolic blood pressure fell by 11 (4 
- 17) mm Hg (p < 0.05)(Fig. 1). Systolic blood pressure fell by 13 (8 - 18) mm Hg 
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Figure 2. Effect of OOAVP (400 ng/!<g Lv. in 10 minutes) on plasma 
renin, noradrenaline, and t-PA:ag in B healthy volunteers (II-II), 
and 8 subjects with essentlal hypertension (e--e). Data 
presented as mean ± sd, 
(p < 0.01). Heart rale rose by 19 (15· 23) bpm (p < 0.001). Renin rose by 120 (43·198) 
% (p < 0.001) , and noradrenaline by 90 (48·131) % (p < 0.001), and t·PA:ag by 240 
(202· 277) % (p < 0.001) (Fig. 2). 
As expected, the baseline blood pressure readings in the hypertensive subjects 
were higher than in the heallhy subjects (p < 0.01). Baseline heart rate, renin, 
noradrenaline and t·PA:ag were not different between the two groups. The effects of 
DDAVP on diastolio pressure and heart rate, and on renin, noradrenaline and t-PA:ag were 
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also not different between the two groups. The hypertensives however showed a fall in 
systolio pressure, whioh was not observed in the normal volunteers. 
10 20 
Infusion 
30 40 50 
(min) 
Figure 3. Plasma DDAVP levels in 6 subjects with essential 
hypertension after the infusion of DDAVP (400 nglkg i.v. in 10 
minutes). 
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DDAVP was measured in the plasma samples from six of the hypertensive 
subjects. Peak plasma levels at the end of the infusion were 2.85 (1.93 - 4.22) ng/ml (Fig. 
3). DDAVP disappeared from plasma mono exponentially with an elimination half life of 48 
(27 - 86) minutes. The distribution volume of DDAVP was calculated to be 0.29 (0.22 -
0.36) l!kg. 
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4.4.2 Incremental low doses 01 DDAVP 
The subjeots with essential hypertension receiving incremental doses of DDAVP 
experienced lacial lIushing. One subjecl reported laciaillushing after Ihe second dose 01 
DDAVP (cumulative dose 25 ng/kg). Four subjecls experienced laciaillushing aller Ihe 50 
ngll<g dose, and live aller the 100 ngll<g dose. The eflecls 01 DDAVP on blood pressure 
and heart rale are depicled in FigA. Bolh syslolic and diaslolic blood pressure showed a 
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Figure 4. Effect of Incremental doses of ODAVP (cumulaUve dose 
12.5 to 400 ngJ1<g at 15 minute Intervals) on blood pressure and 
heart rate In 10 subjects with essential hypertension. Data presented 
as mean ± sd. Systolic and diastolic pressure were significantly 
different from baseline (p < 0.05) at 100 to 400 ngfkg doses. Heart 
rate was significantly different from baseline (p < 0.05) at 50 to 400 
ng/kg doses. 
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Figure 5. Effect of incremental doses of DDAVP (cumulative dose 
12.5 to 400 nglkg at 15 minute intervals) on plasma renin, 
noradrenaline, and t-PA:ag In 10 subjects with essential 
hypertension. Data presented as mean ± sd. Renin and 
noradrenaline were sIgnificantly different from baseline at (p < 0.05) 
100 to 400 nglkg doses. t-PA:ag was significantly different from 
baseline at 200 and 400 ng/kg doses (p < 0.05). 
dose-dependenl decrease. Syslolio pressure fell to 19 (11 - 28) mm Hg below baseline (p 
< 0.001) after Ihe highesl oumulative dose (400 nglkg). Diaslolio pressure fell 10 13 (6 - 19) 
mm Hg below baseline (p < 0.001). Heart rale, renin, noradrenaline and I-PA:ag all 
showed a dose dependenl inorease (Fig.4 and 5). Heart rale inoreased wilh 21 (16 - 25) 
bpm (p < 0.001). Renin rose wilh 68 (45 - 92) % (p < 0.001). Noradrenaline showed a 129 
71 
(91 - 166) % (p < 0.001) increase. and t-PA:ag rose by 233 (110 - 355) % (p < 0.001). 
Analysis 01 the effects of the individual doses of DDAVP revealed that the increase 
in heart rate of 7 (4 - 10) bpm we observed was statistically signilicant (p < 0.05) after the 
50 nglkg dose. The first statistically significant changes in blood pressure were observed 
after the 100 ng/kg dose. With this dose systolic pressure fell by 12 (5 - 20) mm Hg (p < 
0.05). and diastolic pressure by 10 (5 - 15) mm Hg (p < 0.05) from baseline. Both renin 
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Figure 6, Effect of Incremental doses of DOAVP (cumulative dose 
12.5 to 200 ng/kg at 15 minute Intervals) on blood pressure and 
heart rate in 3 patients with autonomic failure. Systolic and diastolic 
pressure were significantly different from baseline (p < 0.05) at 25 to 
200 ng.kg doses, 
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and noradrenaline showed a statistically signifioant ohange from baseline after the 100 
ng/kg dose. Renin increased by 31 (11 - 50) % (p < 0.05). and noradrenaline by 45 (27 -
62) % (p < 0.05). A significant increase in t-PA:ag of 134 (71 - 197) % (p < 0.05) was 
observed after the 200 nglkg dose. 
In the patients with autonomio failure DOAVP oaused a dose dependent fall in 
blood pressure (Fig.6). Already the second dose of DDAVP (cumulative dose 25 nglkg) 
caused a slatistically significant fall in systolic blood pressure of 16 (15 - 18) mm Hg 
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Figure 7. Effect of incremental doses of DDAVP (cumulative dose 
12.5 to 200 nglkg at 15 minute intervals) on plasma renin and 
noradrenaline in 3 patlents with autonomic failure. 
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(median, range) (p < 0.05) and diastolic pressure of 8 (5 - 12) mm Hg (p < 0.05). No 
changes in heart rate were observed in these patients. In two out of the three patients 
renin increased after the highest dose of DDAVP (Fig.?). Noradrenaline did not show any 
significant change. 
4.5 Discussion 
The effects of a high dose of DDAVP (400 ngll<g Lv. in 10 minutes) on blood 
pressure, heart rate, and the plasma levels of renin. noradrenaline and t-PA:ag, in the 
eight healthy volunteers who participated in this study were not different from those 
described previously4,6, These effects are compatible with the view that in normal subjeots 
DOAVP acts as a vasodilator. Our results indioate that this is also true for subjects with 
essential hypertension. From Fig.l it appears that the effect of DDAVP on heart rate may 
be somewhat blunted in the subjeots with essential hypertension as compared to the 
heallhy volunteers. This might be related to the welt known decrease in baroreflex 
sensitivity in hypertension. However, the difference in heart rate response was statistioally 
not signifioant. In the healthy volunteers DDAVP caused a fall in diastolio blood pressure 
without a change in systolic pressure. In the hypertensives both diastolic and systolic blood 
pressure fell. This also might be related to a diminished baroreflex response. 
The dose-response study in the hypertensives showed significant effects on blood 
pressure, heart rate, and the plasma levels of renin and noradrenaline at doses 2 to 4 
times lower than given during the single high~dose infusion. 
The patients with autonomic failure showed marked hypotensive responses to DDAVP at 
doses that were even 8 times lower than the single high dose. As expected, no changes in 
heart rate were observed in the autonomic failure patients and the lack of sympathetic 
counterregulation might welt explain the increased response of blood pressure to DDAVP. 
The rise in plasma noradrenaline after DDAVP is probably a sign of sympathetic 
stimulation in response to vasodilatation. The rise in t~PA:ag might also be a response to 
vasodilatation. It is also possible that the rise in t~PA:ag is a direct consequence of Vz-
receptor stimulation. 
In the patients with autonomic failure we found a blunted renin response to DDAVP. 
This supports the view that the rise in renin after DDAVP in normal volunteers and in 
subjects wilh essential hypertension is secondary to sympathetic stimulation and not a 
direct result of V,-receptor stimulation. The rise in renin after the highest dose of DDAVP in 
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two patients with autonomio failure is possibly caused by a fall in renal perfusion pressure 
related to the fall in blood pressure18,19. 
The distribution volume and plasma half life of DDAVP we found are in accordance 
with other studiesw ,21. Our dose-response studies showed signifioant effects on blood 
pressure and heart rate at doses that were 4 to 8 times lower than the high dose that was 
used in the single dose infusions. The plasma DDAVP levels we found after single high-
dose DDAVP infusion were much higher than the natural AVP levels that can occur under 
physiological and certain pathologioal oonditionsll ,12. From the distribution volume and 
plasma half life we estimate that in the patients with autonomic failure after the lowest 
hypotensive dose (cumulative dose 50 ng/kg) plasma DDAVP levels were 150 - 200 pglml. 
We estimate that in the hypertensive subjeots the lowest hypotensive dose (cumulative 
dose 100 nglkg) resulted in plasma levels of 300 - 400 ng/kg. These plasma levels are 
comparable to the levels of AVP that are found under pathological conditions with 
stimulated AVP secretion. 
We oonolude that under certain pathological conditions endogenous AVP may 
oause V2-receptor-mediated vasodilatation. In these conditions this meohanism possibly 
serves to attenuate the V,-receptor-mediated vasoconstrictor effect of AVP. 
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Chapter five 
EFFECTS OF 1-DESAMINO-8-D-ARGININE VASOPRESSIN (DDAVP) ON RENAL 
HEMODYNAMICS AND RENIN SECRETION IN SUBJECTS WITH ESSENTIAL 
HYPERTENSION. 
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5.1 Summary 
Intravenous (i.v.) infusion of the selective vasopressin (V,) agonist 1-desamino-
8-0-arginine vasopressin (DDAVP) in humans causes a fall in blood pressure, an 
inorease in heart rate, and a rise in plasma renin and noradrenaline. The present 
study was designed to demonstrate the vasodilatory properties of DDAVP in the renal 
circulation. 
Seven male hypertensive subjects (31-63 years), received an i.v. infusion of 
DDAVP (400 ng/kg in 10 minutes) at the time of renal vein catheterization and renal 
angiography as pert of the diagnostic work·up of their hypertension. '" I-Hippurate 
clearance was used to measure effective renal plasma flow (ERPF). True renal 
plasma flow was calculated as ERPF divided by the extraction ratio of '''I-hippurate 
(E",,). 
125f-Thalamate clearance was used to measure glomerular filtration rate (GFR). 
Measurements were made before and 15-20 minutes after administration of DDAVP. 
Angiography was performed after these measurements were made. In all patients the 
renal arteries were normal and EhlP and the extraction of 1251-lhalamate (E1hal) were not 
different for the leff and right kidney. 
After DDAVP systolic blood pressure fell from 163 (114-211) mm Hg (mean, 
95% confidence interval) to 146 (113-179) mm Hg (p < 0.05). Diastolic blood pressure 
fell from 103 (70-137) mm Hg to 87 (58-117) mm Hg (p < 0.01). Heart rate rose from 
79 (48-110) bpm to 102 (61-143) bpm (p < 0.001). The plasma level of "'I-hippurate 
did not change, and E"p of the leff kidney fell from 0.77 (0.68-0.87) to 0.72 (0.57-
0.87)(p < 0.05). and of the right kidney from 0.80 (0.75·0.84) to 0.71 (0.61-0.82)(p < 
0.005). E'lm of the leff kidney fell from 0.18 (0.13-0.24) to 0.16 (0.08-0.24)(p < 0.05), 
and of the right kidney from 0.22 (0.18-0.26) to 0.17 (0.1 0-0.25)(p < 0.005). 
These data indicate that the true renal plasma flow was increased after 
DDAVP and filtration fration was decreased. Peripheral plasma renin rose by 175 (55-
564) percent (p < 0.001), and the renal vein-to-artery renin ratio of the leff kidney rose 
from 1.44 (0.83-2.05) to 1.70 (0.97-2.43)(p < 0.05), and of the right kidney from 1.43 
(1.05-1.81)10 1.85 (0.9B-2.72)(p < 0.05). 
We conclude that stimulation of renal V,-receptors by DDAVP leads to renal 
vasodilation and increased renin recretion. The data provide evidence for the 
existence of functional renal V2R receptors at sites other than the renal tubular cells. 
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5.2 Inlroductlon 
The nonapeptide arginine vasopressin (AVP) has both potent vasoconstrictor 
and antidiuretic effects1,2, The vasoconstrictor action of AVP is mediated by vascular 
VI-receptors, while the antidiuretic effect is mediated by V2-receptors on the tubular 
cells of the renal collecting ducts'. 
1-0esamino-8-0-arginine vasopressin (OOAVP) is a synthetic analog of AVP 
with selective V2-receptor agonistio properties4,6, Because of its potent antidiuretic 
effect and its lack of vasoconstrictor action, DDAVP is used in the treatment of 
patients with central diabetes insipidus6, High doses of DDAVP induce an increase of 
the plasma levels of clotting factor VIII, von Willebrand factor and tissue type 
plasminogen activator7,8. Because of the effects on olotting factor VIII and von 
Willebrand faotor, high doses of DDAVP are used in various haemorrhagia disorders9, 
High doses of OOAVP also cause faciaillushing, a fall in blood pressure, a marked 
increase in heart rate, and a rise of plasma noradrenaline, all compatible with 
systemic vasodilation 'O. 
The present study addresses the possible vasodilatory effects of OOAVP in the 
renal circulation. 
5.3 Patients and methods 
Seven male patients, aged 31-63 years, were studied after they had given their 
informed consent. They were admitted to our hospital for a diagnostio work-up, 
beoause their hypertension was diffioult to oontrol. Urine analysis and serum 
eleotrolytes, urea and creatinine Were normal. Urinary excretion of vanillylmandelio 
acid was also normal. All medication was stopped for at least two weeks prior to the 
study. 
Renal funotion and perfusion,were measured using constant infusion olearance 
techniques without urine collection '1 ,12,13, A solution containing 0.5 J.lCi/ml of'31 1-sodium 
iodohippurate (l3'l-hip) (50,000 c.p.m.lml) and 2 ~Ci/ml '''l-iothalamate ('''1-
thal)(50,OOO c.p.m.lml) was infused at a rate of 0.1 ml/min after a bolus of 0.20 ml/kg 
of this solution had been given. Approximately 90 minutes after the beginning of the 
infusion of 1311_hip and 125l-thal, angiography catheters were introduced, by using the 
Seldinger technique, in a femoral artery and the ipsilateral femoral vein. Approximately 
35 minutes later, blood samples were taken simultaneously from the renal vein and 
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abdominal aorta, first at one side, and immediately thereafter on the other" (Fig.f). 
DDAVP (Minrin, Ferring, Malmo, Sweden), 400 nglkg dissolved in 100 ml saline, was 
infused in a peripheral vein in exactly 10 minutes (Fig.1). Renal vein sampling was 
repeated 20 minutes after the infusion of DDAVP (Fig. f). A renal aniogram was made 
after completion of the study. 
Peripheral venous blood samples were taken at regular time intervals as 
indicated in Fig.1. 
minutes 
o 60 80 100 120 140 160 
Infusions: 
~~1-+-+-~~~-+-+~ 
131 I-hippurate 
12Sl-thalamate 
DDAVP 
peripheral vein blood sampling: 
131 '-hippurate 
125'.thalamate 
renin 
X 
X 
renal artery and vein blood sampling: 
13I'-hfppurate 
." '·thalamate 
renin 
X X X X X 
X X X X X 
X 
X 
X 
X 
Figure 1. Diagram of the timing of the infusion of DDAVP, and 1311_hippurale, and 
125/-thalamate, and the acquisition of blood samples. 
XXX 
XXX 
X 
X 
X 
X 
All blood samples were immediately centrifuged, 1251 and 131 1 radioactivity levels 
in plasma were measures separately. The single kidney extraction ratios of t311_sodium 
hippurate (Ehi.J and '''Hothalamate (E.,,) were calculated as (A-V)/A, where A = 
radioactivity in plasma from the abdominal aorta, and V = radioactivity in plasma from 
the renal vein. The total extraotion effioiency (both kidneys) was oaloulated as the 
mean of the extraction ratios on each side. In all blood samples plasma renin was 
measured with an enzyme kinetic assay, in which the in vitro generated angiotensin I 
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was measured by radioimmunoassay14. 
Blood pressure was measured intra-arterially from the catheter in the 
abdominal aorta. Heart rate was determined from a simultaneously recorded ECG 
signal. 
The data were analyzed using a one way analysis of variance for repeated 
measures in the same subjects. Data on plasma renin were analysed after log 
transformation. 
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Figure 2. Effect of DDAVP (400 nglkg i.v. in 10 minutes) on systolio 
blood pressure (e--e), diastolio blood pressure (M_), and 
heart rate (Ja.--Ja.) (mean ± sd). "* P < 0.05; ** p < 0.01; 
.*** P < 0.001. 
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5.4 Results 
Renal angiograms were normal in all seven patients. As shown in Fig.2, 
DDAVP infusion caused a fall in systolic blood pressure by 9.5 (0.8-19.9) percent 
(mean, 95% confidence interval)(p < 0.05) and in diastolic pressure by 15.2 (0.2-30_1) 
percent (p < 0.01). This effect was accompanied by a 21.7 (4.0-39.4) percent (p< 
0.001) increase in heart rate. 
1,200 
f··········· r···· l··H i!''''' 1,000 if ._ E ~ :e .. _.----g E .2 E 'C a. 800 ~ .!!. 
600 
400 f ! f--fft fft 200 
60 80 100 120 140 160 
(mtn) 
DDAVP 
Figure 3. Radioactivity from 1251-lhalamate (B- - -B) and 1311_hippurate (e_) In 
plasma measured before and after DDAVP (400 ngJ1<g Lv. In 10 minutes) (mean ± sd). 
After 90 minutes of '''I-hip and 12'I-thal infusion the plasma levels of both 
compounds were stable (Fig.3). The infusion of DDAVP did not significantly alter the 
plasma levels of 1311_hip and 12SHhai (Fig.3). However, Ehip and Elha1 were reduced by 
DDAVP; Eh•P of the left kidney fell from 0.77 (0.68-0.87) to 0.72 (0.57-0.87) (p < 0.05) 
and of the right kidney from 0.80 (0.75-0.84) to 0.71 (0.61-0.82) (p < 0.005), and E
'ha1 
of the left kifney fell from 0.18 (0.13·0.24) to 0.16 (0.08-0.24) (p < 0.05) and of the 
right kidney from 0.22 (0.18-0.26) to 0.17 (0.10·0.25) (p < 0.005)(Fig,4). 
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Figure 4. Single kIdney extraction of '311~hjppurate and 12S_thafamate 
of the left kidney and the right kidney measured before and after 
DDAVP (400 nglkg I.v. in 10 minutes). * p < 0.05; ** P < 0,005, 
Peripheral venous plasma renin rose by 175 (55-564) percent (p < 0.001), and 
renal vein-to-artery renin ratio of the left kidney rose 1.44 (0.83-2.05) to 1.70 (0.97-
2.43) (p < 0.05), and of the right kidney from 1.43 (1.05-1.81) to 1.85 (0.98-2.72) (p < 
0.05) (Fig.5). 
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Figure 5, Peripheral venous renin (.A--A) and single kidney vein-
to-artery renin ratio of the left kidney (e------8) and right kidney 
(11- - -.) measured before and after DDAVP (mean ± sd). 
"* p < 0.05; ** P < 0,001. 
5.5 Discussion 
The hemodynamio effeots of an Lv. infusion of 400 n911<9 DDAVP in healthy 
volunteers are a slight fall in diastolio blood pressure without a change in systolio 
blood pressure9,H" Together with these changes in blood pressure marked increments 
in heart rate and in the plasma levels of renin and noradrenaline are observed. In 
previous work we demonstrat~d these effeots to be caused by extrarenal V 2-receptor 
stimulation'6, The patients with essential hypertension that participated in the present 
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study showed not only a fall in diastolio blood pressure but also in systolic blood 
pressure. Possibly the blood pressure in hypertensive SUbjects is somewhat more 
responsive to the vasodilator aotion of DDAVP. 
In the present study we assessed the effects of DDAVP on renal 
hemodynamios by measurements of the peripheral and renal venous plasma levels of 
1311_hip and 125Hhai during consiant systemic infusion of these compounds10,ll, As 
shown in Fig.3, the plasma levels of both 'OIl_hip and '''I-thai had reached a stable 
plateau prior to the infusion of DDAVP. Thus it was possible to oalculate ERPF and 
GFR as the clearances of 1311_hip and 1251_thal respectively by dividing the infusion 
rates by the steady state plasma levels. Suoh oaloulations were not possible after 
DDAVP infusion, because the time inteIVal between the infusion of DDAVP and the 
last measurements of ! 31 1_hip and 1251_thal was to short (30 minutes) to reaoh a new 
steady state. For ERPF a semiquantitative estimate of the effect of DDAVP could be 
madel because in patients with a normal renal function the plasma half-life of 1311_hip 
is about 20 minutes. For GFR such a semiquantitative estimate cannot be made 
because of the longer plasma half-life of '''I-thaI. 
Thus, since plasma 1311_hip did not change after DDAVP, we may conclude that 
there was little or no change in ERPF. This, together with the observed fall in Eh!p is 
an indication that the true renal plasma flow was increased by DDAVP. This inorease 
in RPF occurred while blood pressure fell. Thus DDAVP had caused renal 
vasodilatation. As with other drugs causing renal vasodilation the renal vasodilatory 
effect of DDAVP was associated with a fall in E"" which may be explained by a 
shortened plasma transit time through the kidneyI2.17. 
Ethal is equal to single kidney filtration fraction. The fall in Ethal we observed 
therefore demonstrates a fall in filtration fraction. 
DDAVP caused a marked rise in peripheral plasma renin. Our study 
demonstrates that this was due to increased renal secretion, since both renal plasma 
flow and renal vein-Io-artery renin ratio were increased after DDAVP. Infusion of AVP, 
in contrast to DDAVP, causes inhibition of renin secretion through stimulation of V1-
receptors on juxtaglomerular oells9.18.19.2O. At extremely high conoentrations, DDAVP 
oan aot as an antagonist of the AVP-induoed inhibition of renin secretion from kidney 
slioes9. DDAVP itself, on the other hand, did not stimulate renin secretion9. Thus it is 
unlikely that the inorease in renal renin secretion after DDAVP we observed, is a 
direct result of V2-reoeptor stimulation. It rather is a secondary response to renal 
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vasodilatation. Possibly, sympathetic stimulation may also contribute to the increased 
release of renin after DDAVp34.21 . 
In previous work it was demonstrated that DDAVP oauses its vasodilatory 
effect through V2-receptor stimulation1s,22, V2-reoeptors have been localized in the 
brain, and it has been suggested that DDAVP exerts its vasodilator action through the 
central nervous system23. One would expect such effect to be accompanied by a 
reduotion in sympathetio tone. DDAVP however is known to oause an increase in the 
activity of the sympathetic nervous system as is reflected in the increase in plasma 
noradrenaline9.15 • Furthermore, in dogs with a destroyed central nervous system, the 
selective V2-reoeptor agonist 4-valine-8-D-arginine vasopressin (VDAVP) has been 
shown to cause vasodilation through a peripheral action24. A more recent study in 
humans disclosed that even AVP can oause vasodilation in the forearm through 
stimulation of peripheral V 2-receptors25. It may therefore be concluded that, although 
until recently the AVP receptors in the vascular wall were considered to be of the V,-
type26, and V2-receptors were considered to be located exclusively on renal tubular 
cells27, it is unlikely that DDAVP oauses its vasodilator action in man via the central 
nervous system. 
It is possible that DDAVP causes its vasodilator action by stimulated 
production of vasodilatory prostaglandins like PGE, and PGI" AVP is known to 
stimulate renal PGE2 production in rats via Vcreceptors on glomerular mesangial 
cells2a.29,30,3', whereas DDAVP had not such efteot26• It has been reported that both 
AVP and DDAVP stimulate PGE, production in patients with central or nephrogenic 
diabetes insipidus32• However the response to ODAVP was much weaker than to AVP. 
PGI2 synthesis by vascular smooth muscle ce/ls, from rat mesenterio arteries and 
aorta, can be stimulated by AVP but not by DDAVP"''', In humans, DDAVP has been 
reported to cause an increase in the production of PGI233. However, in more recent 
studies this could not be confirmed34,35. Furthermore, blockade of prostaglandin 
synthesis by high dose aspirin did not inhibit the effects on blood pressure and heart 
rate of DDAVP", It seems therefore untikely that increased PGI, production can 
account for the vasodilator action of DDAVP, 
We conclude that DDAVP causes renal vasodilatation via vascular V2-
receptors, despite the fact that up to now peripheral V,-receptors have only been 
demonstrated in renal medullary tubules and colleoting ducts. Since the amounts of 
DDAVP we infused result in plasma levels far exceeding the AVP levels that occur 
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under physiologioal and in abnormal oonditions37•38, like dehydration or hemorrhagio 
shock, it remains to be seen if V 2~receptor~mediated vasodilation is a physiologioally 
important effect contributing to the overall hemodynamio aotions of endogenous AVP. 
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Chapter six 
SUMMARY AND CONCLUSIONS 
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6.1 Introduction 
In humans arginine vasopressin (AVP) is the natural antidiuretio hormone. Apart from 
its antidiuretio aotion, AVP can cause a variety of other effects like vasoconstriction, platelet 
aggregation, glycogen breakdown in Ihe liver, Ihe release of clotting faclor VIII (FVIII:C), 
von Willebrand faclor (vWF:ag), and tissue·lype plasminogen activalor (I-PA) from 
endothelium, and inhibition of renin release from juxtaglomerular cells. In the central 
nervous system AVP aots as a neurotransmitter. 
AVP causes ils effecls by stimulation of two differenllypes of receplors'. The 
vasoconstriotor effect is mediated by stimulation of vascular V I-receptors. Stimulation of this 
receptor causes an inorease in phosphatidylinositol breakdown and a rise in oytosolic 
oalcium. Platelet aggregation. glycogen breakdown and inhibition of renin release are also 
mediated by VI-receptors. The antidiuretic action is mediated by stimulation of V2-receptors 
located on tubular cells of the renal collecting ducts. Binding of AVP to this receptor causes 
activation of adenyl ate cyclase, which leads to a rise in intracellular 3'5'adenosine 
monophosphale (c-AMP). 
1-Desamino-8-D-arginine vasopressin is a synthetic analog of AVP whioh has virtually 
lost the vasopressor aotion has but retained the antidiuretic properties of AVp2. Beoause of 
its seleotive V2-reoeptor agonist effeot, DDAVP is used as a treatment in patients with 
central diabetes insipidus. 
Bolh AVP and also inlravenous adminislration of a high dose of DDAVP (200 - 400 
nglkg) have been shown to oause an inorease in the plasma levels of FVIII:C, vWF:ag, and 
I-PA'. Allhese doses facial flushing and palpilations are reported as side effecls of 
DDAVP, suggesting that its infusion causes hemodynamio changes. 
6.2 Aim of the thesis 
This thesis oontains the results of the studies that were undertaken to investigate the 
hemodynamic effecls, as well as Ihe effecls on FVIII:C, vWF:ag, and I-PA of inlravenous 
administration of DDAVP in man. Our objective was to eluoidate the meohanism by which 
DDAVP exerts Ihese effecls, and 10 evaluale Ihe possibilily Ihallhis mechanism can also 
be activaled by endogenous AVP. 
93 
6.3 DDAVP In healthy volunteers 
In twelve apparently healthy volunteers we investigated the hemodynamic responses 
and the ellects on FVIII:C, vWF:ag, and t·PA 01 DDAVP, using a double blinded placebo 
controlled study design. The participants in this study were randomly assigned to either 
DDAVP (400 nglkg Lv. in 10 minutes) or a comparable amount of solvent. Placebo had no 
effect on any of the parameters measured. DDAVP caused a minor fall in diastolio blood 
pressure without a change in systolio pressure. This was accompanied by a striking 
inorease in heart rate and a rise in plasma renin and noradrenaline. These findings support 
the view that at these doses DDAVP causes vasodilatation and baroreflex-mediated 
sympathetic stimulation. DDAVP caused also a rise in FVIII:C, vWF:ag, and both t-PA-
antigen (t-PA:ag) and t-PA-activity (t-PA:act). The increase in t-PA:act was accompanied by 
a fall in plasminogen activator inhibitor (PAl). From this study we concluded that DDAVP 
itself and not another constituent of the DDAVP solution causes vasodilatation and a rise in 
plasma FVIII:C, vWF:ag, and t-PA:ag and t-PA:act. 
6.4 DDAVP In patients with congenital nephrogenic diabetes Insipidus 
Derkx at al.4 found that high concentrations of DDAVP can inhibit V1-reoeptor 
mediated elleets 01 AVP. They concluded that the vasodilator effect of DDAVP might be 
caused by antagonism of the VI-receptor mediated vasoconstrictor effeot of endogenous 
AVP. However, it is unlikely that the infusion of 400 nglkg of DDAVP can result in plasma 
levels as high as the DDAVP concentrations that were shown to oause a VI-reoeptor 
antagonistic effect in vitro. 
Since DDAVP is a seleotive V2-receptor agonist, it is likely that its vasodilator action is 
caused by V2-receptor stimulation. To test this hypothesis we inlused DDAVP (400 nglkg 
i.v. in 10 minutes) into three patients with congenital nephrogenic diabetes insipidus (NOI). 
Patients with NDI sufler from polyuria and polydipsia due to an X-linked reeessive genetic 
defect of the V2-receptor or a defect at the post-receptor level. This defect is propably not 
restricted to the renal tubules. Patients with congenital NDI may therefore expected to be 
unresponsive to DDAVP. Indeed single high dose of DDAVP did not change blood 
pressure, heart rate and the plasma levels of renin, noradrenaline, FVIII:C, vWF:ag, t-
PA:ag, t-PA:act, and PAL The absence of these extrarenal effects of DOAVP in these 
patients suggests that in healthy volunteers these effects are mediated via V2-receptors. 
II is unlikely that the patients with NDI not only have a V2-receptor defect but also a 
diminished V1-receptor function, because plasma AVP levels were normal, which argues 
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against down-regulation of V1-receptors. Moreover infusion of AVP in one af the patients 
caused a normal pressor response. 
The lack of vWF:ag and t-PA responses in hte NDI patients was not caused by 
generalized endothelial dysfunction. The responses to venous ocolusion in the patients with 
NDI were similar to those in five normal volunteers. 
We therefore oonclude that in normal volunteers, DDAVP causes vasodilatation and 
the release from endothelium of FVIII:C, vWF:ag, t-PA:ag and t-PA:act through V,-reoeptor 
stimulation. 
6.5 DDAVP In subjects with essential hypertension 
Eight subjects with essential hypertension and eight normal volunteers received a 
single high dose of DDAVP (400 nglkg Lv. in 10 minutes). The vasodilator effect and the 
effects on t-PA:ag of DDAVP were compared between the two groups. In contrast to the 
normal volunteers DDAVP in the hypertensives caused not only a fall in diastolic blood 
pressure but also a fall in systolic pressure. The rise in heart rate in the hypertensives 
appeared to be somewhat blunted as compared to the normal volunteers. Both the fall in 
systolip pressure and the somewhat blunted rise in heart rate might be related to the well 
known diminished baroreflex sensitivity in hypertension. The responses of renin, 
noradrenaline and t-PA:ag were the same in the hypertensives and the normal volUnteers. 
We conclude that the effects of DDAVP in the subjects with hypertension are not 
essentially different from those in healthy volunteers. 
6.6 DDAVP plasma levels after a single high dose 
In six of the subjects with essential hypertension we measured DDAVP plasma levels 
after the infusion of a single high dose (400 nglkg Lv. in 10 minutes). These plasma levels 
were much higher than the natural AVP levels that can be found under physiological 
conditions in man. They are also higher than the AVP levels under pathological conditions 
with stimulated AVP release. It remains therefore uncertain whether the observed 
vasodilator eHect of V2-receptor stimulation by DDAVP can also be elicited by endogenous 
AVP. 
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6.7 Incremental low doses of DDAVP 
We investigated the hemodynamio effeots of inoremental low doses of DDAVP in ten 
subjects with essential hypertension and in three patients with orthostatio hypotension due 
to peripheral autonomic neuropathy. We expected blood pressure of patients with loss of 
sympathetio function to be hyperresponsive to the vasodilator action of DDAVP. In the 
hypertensives DDAVP had signilioant effeots on blood pressure and heart rate at doses 4 
to 8 times lower than the single high dose infusion. The patients with orthostatio 
hypotension showed a significant fall in blood pressure at even lower doses without any 
ohange in heart rate. We estimate that the lowest hypotensive dose 01 DDAVP in the 
hypertensives and in the patients with autonomic failure resulted in plasma levels that are 
oomparable to the levels of AVP that oan be found under pathologioal oonditions with 
stimulated AVP secretion. We conclude therefore that under certain pathological conditions 
endogenous AVP may cause V2-receptor mediated vasodilatation. 
As expected, DDAVP did not cause a rise in noradrenaline in the patients with 
autonomio failure. These patients also showed a diminished responsiveness of renin to 
DDAVP. This supports the view that the rise in renin after DDAVP in both the normal 
volunteers and the hypertensives is not a direct result of V2-receptor stimulation but is 
secondary to sympathetic stimulation. 
6.8 Effeots of DDAVP on the renal circulation and on renin release 
The possible vasodilator aotion of DDAVP in the renal oiroulation and the effeot on 
renal renin seoretion were investigated in seven patients wilh essential hypertension. The 
clearanoe of 1311-hippurate C31 1-hip) as a measure of effective renal plasma flow (ERPF), 
and the clearanoe of t25Hhafamate C25Hhaf) as a measure of glomerular filtration rale 
(GFR) were measured belore and after the inlusion of a single high dose of DDAVP (400 
ng/kg Lv. in 10 minutes). The renal clearanoes were calculated from the peripheral venous 
plasma levels and the infusion rate of both compounds during a constant infusion. Single 
kidney extraction ratios of t311_hip (En:,) and 125Hhal (E1na1) and the renal vein-Io-artery renin 
ratio's were measured by renal vein sampling before and after DDAVP. Plasma I3II-hip did 
not ohange alter DDAVP, whioh indioated that there was litUe or no ohange in ERPF. Thus. 
the signifioant fall in En:p we observed, is propably oaused by an increase in true renal 
plasma flow (RPF). This inorease in RPF ooourred while blood pressure fell. We oonolude 
therefore that DDAVP in the dose we used oauses renal vasodilatation. 
The renal vein-la-artery renin ratios showed a significant rise, despite the inorease in 
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RPF. This demonstrates that the release of renin by the kidney is increased, and this has 
led to the rise in peripheral vein renin. 
6.9 Conclusions 
From the studies described in this thesis it can be concluded that a high dose of 
DDAVP causes systemic and renal vasodilation through V 2~receptor stimulation. The 
observed effects of lower doses of DDAVP indicate that V,-receptor mediated 
vasodilatation may also occur in certain pathological conditions with elevated plasma levels 
of endogenous AVP. Such high plasma AVP levels are found when circulating blood 
volume is severely reduced. Under these circumstances stimulation of V2-receptors on 
renal tubular cells reduces urine produotion, and helps to preserve circulating volume. V,-
receptor-mediated vasoconstriction causes an increase in peripheral vascular resistance, 
and this helps to maintain blood pressure. It is possible that V2-receptor mediated 
vasodilatation serves as a mechanism to protect vital organs from the vasoconstrictor effect 
of V1~receptor stimulation. 
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7.1 Inleiding 
Arginine~vasopressine (AVP) is bij de mens het natuurJijke antidiuretisch harmoon. 
Naast de antidiuretische werking, kan AVP diverse andere effecten veroorzaken zoals 
vasoconstriotie, plaatjes-aggregatie, glycogeen-afbraak in de lever, en de afgifte van 
stollingsfactor VIII (FVIII:C), von Willebrand faclor (vWF:ag) en weefsel-plasminogeen 
activator (t-PA) door endotheel, en inhibitie van ranine-secratia uit juxlaglomerulaire cellen. 
In het centrale zenuwstelsel heeft AVP een neurolransrnilter-functie. 
De effectan van AVP worden veroorzaakt door stimulatie van twae versohillende 
receptoren
'
, Het vaatvernauwende effect wordt veroorzaakt door stimulatie van V,-
receptoren in de vaatwand. Stimulatie van deze receptor laidt tot aen toename van de 
phosphalidylinosilol omzeUing en een slijging van hel calcium in de cytosol. Plaaljes-
aggregatie, glycogeen~afbraak en inhibilie van renine-seoretie worden eveneens 
veroorzaakt via V1-receptoren. De antidiuretische werking van AVP verloopt via activatie 
van V2-receptoren op de tubuluscellen van de verzamelbuisjes in de nier. Binding van AVP 
met deze receptoren aotiveert adenylaatoyolase, dil laid! vervolgens tot een stijging van het 
inlraceliulair 3'5'adenosine monofosfaal (c-AMP). 
l-Desamino-8-D-arginine vasopressine (DDAVP) is een synlhelisch AVP-derivaal', 
dat de vaatvernauwende werking verlaren haeft, maar de antidiuretische werking heeft 
behouden. Vanwege deze selectieve V 2-receptor-agonistische werking wordt DDAVP 
gebruikt voor de behandeling van patienten met centrale diabetes insipidus. 
Van zowel AVP als van inlraveneuze toediening van hoge doses DDAVP (200 - 400 
nglkg) is gebleken dat dil een slijging van FVIII:C, vWF:ag en t-PA in plasma kan 
veroorzaken3 , Blj deze doseringen ziJn roodheid en warmtegevoel in het gezichl en 
hartkloppingen gemeld als bi)werkingen van DDAVP. Deze effeclen wi)zen erop dal DDAVP 
hemodynamische veranderingen veroorzaakt. 
7.2 Doel van het onderzoek 
Oit proefschrift bevat de resultaten van de studies die werden gedaan om de 
hemodynamische effeclen alsmede de effeclen op FVIII:C, vWF:ag en I-PA van 
intraveneuze toediening van ODAVP bij de mens te onderzoeken. Het doel van het 
onderzoek was om op Ie helderen via welke mechanisme DDAVP deze effeclen 
veroorzaakt, en om de mogelijkheid te evalueren dat dit mechanisme ook kan worden 
geactiveerd door endogeen AVP. 
IOJ 
7.3 DDAVP bll gelonde vrllwliligers 
In een dubbel·blinde placebo·geoontroleerde studie werd bij twaalf gezonde 
vrijwilligers de hemodynamische effecten van DDAVP, en de effecten op FVIII:C, vWF:ag 
en t·PA onderzochl. De deelnemers kregen na randomisatie of DDAVP (400 ng/kg i.v. in 
10 minuten) of een vergetijkbare hoeveelheid bewaarvloeistof. Placebo had geen effect op 
de parameters die werden gameten. DDAVP veroorzaakte en geringe daling van de 
diastolische bloeddruk, zonder een dating van de systotische bloeddruk. Dit ging gepaard 
met een opval/ende toename van de hartfrequentie en een stijging van ranine en 
noradrenaline in plasma. Deze waarnemingen ondersteunen de hypothese da! deze dosis 
DDAVP vaalverwijding veroorzaakt, en via de baroreflex tevens sympathious stimulatie 
geeft. DDAVP veroorzaakte ook een stijging van FVIII:C, vWF:ag en van zowel t·PA-
antigeen (t-PA:ag) als t-PA-activiteit (t-PA:act). De stijging in t-PA:act ging gepaard met een 
daling van plasminogeenaotivator~inhibitor (PAl). Uil de resultaten van deze studie 
concluderen wij dat DDAVP zelf, en niet een ander bestanddeel van de DDAVP oplossing, 
vaatvelWijding en de toename in plasma van FVIII:C, vWF:ag, t-PA:ag en t-PA:act, 
veroorzaakt. 
7.4 DDAVP bll patlenten met congenltale nefrogene diabetes Insipidus 
Oerkx at al.4 vanden dat hoge concentraties DDAVP aan V,-receptor-stimulatie 
gerelateerde effecten van AVP kan remmen. Hieruil werd geconcludeerd dat het 
vaatverwijdende effect van DDAVP ZOU kunnen berusten op antagonisme van de V1-
receptor gemedieerde vasoconstrictieve werking van AVP. Het is echter onwaarschijnlijk 
dat infusie van 400 ngikg DDAVP resulteert in plasma concentraties in dezelfde orde van 
graoUe als de concentratie die een V I-receptor antagonistisch effect bleek te hebben in 
vitro, 
DDAVP is een selectieve V2-receptor-agonist. Oaarom is het waarschijnlijk dat de 
vaatverwijdende werking wordt veroorzaakt door stimulatie van V2-receptoren. Teneinde 
deze hypothese te testen werd DDAVP (400 nglkg Lv. in 10 minuten) toegediend aan drie 
pati8nten met congenitale nefrogene diabetes insipidus (NDI). Patienten met congenitale 
NOI lijden aan polyurie en polydipsie als gevolg van een geslachtsgebonden recessief 
genetisch defect van de V,-reoeptor dan wei een deleot op post-receptor niveau. Dit defeot 
is waarschijnlijk niet beperkt tot de verzamelbuisjes in de nier. Van patienten met 
congenitale NDI mag dus velWacht worden dat zij niet reageren op DDAVP. Conform deze 
velWachting, veroorzaakte een enkelvoudige hoge dosis DDAVP geen enkele 
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veranderingen in bloeddruk, hartlrequenlie, renine, noradrenaline, FVIII:C, vWF:ag, t-PA:ag, 
t-PA:act en PAL De afwezigheid van deze extra-renale effecten bij deze patienten wijst 
arop, dal bij gezonde vrijwilligers en essentials hypertonici de extra-renale effecten van 
DDAVP worden veroorzaakt door V 2-receptor stimulatie. 
Het is onwaarsohijnliJk dal de patientsn met congenitale NOI naast een V 2-receptor 
defect tevens een verminderde V,-reoeptor-werking habben, want de plasma AVP spiegels 
waren normaal, hetgeen pleit tegen down-regulatie van V1-receptorsn. Tavens bleek, bij 
€len van de patienten, dal infusie van AVP een normale pressor-reaotie veroorzaakte. De 
afwezige reaclie van vWF:ag en t-PA bij de palienten met congenitale NDI werd niet 
veroorzaakt door een gegeneralizeerde endotheel-dysfunktie. De reacties op veneuze 
Geolusie bij de patienten met congenitale NOI waren gelijk aan die bij een vijftal gezonde 
vrijwilligers. Wij concluderen dat bij gezonde vrijwilligers, DDAVP, door stimulatie van V,-
receptoren, vaatverwijding en vrijmaking uit endotheel van FVIII:C, vWF:ag, t-PA:ag en t-
PA:act veroorzaakt. 
7.5 DDAVP blj essentlale hypertensle 
Acht personan met essentiale hypertensie en acht gezonde vrijwilligers kregen een 
enkelvoudige hoge dosis DDAVP (400 nglkg i.v. in 10 minuten) toegediend. De 
vaatverwijdende werking, en het eUect op t-PA:ag secretie van DDAVP werden vergeleken 
lussen de twee graepen. In tegenstelling lot de normals vrijwHligers, veroorzaakte DDAVP 
hij de essentiale hypertonioi niet aileen een daling van de diaslolische bloeddruk, maar 
tavens aen daling van de systolische bloeddruk. De toename van de hartfrequentie bij de 
hypertonioi varliep iets vlakker dan bij de gezonde vrijwilHgers. Zowel de daling van de 
systolische bloeddruk als het vlakker verloop van de hartfrequentie-stijging kunnen worden 
verklaard uil sen verminderde baroreflex-gevoeligheid bij hypertonici. De reaatie van renine, 
noradrenaline en t-PA:ag op DDAVP, waren niet versohillend in beide graepen. We 
concluderen dat de effecten van OOAVP bij hypertonici niet essentieel verschillen van de 
effecten bij normale vrijwilligers. 
7.6 DDAVP plasma splegels 
Bij zes van de person en met essentiSle hypertensie werden de DDAVP-concentraties 
in plasma gemeten na infusie van een enkelvoudige hoge dosis (400 nglkg i.v. in fO 
minuten). Deze concentraties bleken aanzienlijk hager te zijn dan de concentratie van 
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endogeen AVP in plasma, zoals die onder fysiologische omstandigheden kunnen 
voorkomen bij de mens. De DDAVP-concentraties waren ook hoger dan AVP-concentraties 
in plasma onder palhologisohe omstandigheden die gepaard gaan met gestimuleerde AVP 
secretie. Het blijft dus onzeker of het vaatverwijdend effect van V 2-receptor stimulatie door 
DDAVP, ook kan worden opgewekt door endogeen AVP. 
7.7 Oplopende lage doserlngen DDAVP 
We onderzochten de hemodynamische effecten van oplopende lagere doses DDAVP 
bij tien person en met essentiele hypertensie en drie patienten met orthostatische 
hypotensie door perifere autonome neuropathie. We verwaohtten dat de bloeddruk bij de 
patienten met verminderde sympathicus-funktie een versterkte reacHe op de 
vaatverwijdende werking van DDAVP zouden vertonen. Bi] de hypertonioi had DDAVP 
signifioante effeoten op bloeddruk en hartfrequentie bij doseringen 4 tot 8 maal lager dan 
de enkelvoudige hoge dosering. De patienten met orthostatische hypotensie vertoonden 
een significante daling van de bloeddruk zonder enige verandering in de hartfrequentie bij 
een nog lagere dosis. We schaUen, dat de laagste dosis DDAVP, die een daling van de 
bloeddruk gat bij de hypertonioi en bij de patienten met auto nome dystunktie, resulleerde in 
DDAVP-conoentraties in plasma van dezelfde orde van grooUe als AVP-concentraties zoals 
die kunnen worden gevonden onder pathologische omstandigheden die gepaard gaan met 
een verhoogde AVP-secretie. Wij concluderen hieruit dat onder bepaalde pathologisohe 
omstandigheden endogeen AVP vaatverwijding zou kunnen veroorzaken via V2-receptor 
stimulatie. 
Zoals verwaoht veroorzaakte OOAVP bij de patienten met orlhostatische hypotensie 
geen stijging van het noradrenaline. Tevens vertoonden deze patienten een verminderde 
reaotie van renine op DDAVP. Dit steunt de hypothese dat de renine stijging na DDAVP 
zowel bij gezonde vrijwiHigers als bij essentiele hypertonioi, geen direct gevolg is Van V2-
receptor stimulatie, maar een secundair gevolg is van sympathicus aotivatie. 
7.8 Effeclen van DDAVP op de renale olroulalle en op renlne- seorelle 
De mogelijke vaatverwijdende werking van DDAVP op de renale oiroulalie en het 
effect op de renine-seoretie, werden onderzochl bij zeven patienten met essentiele 
hypertensie. De 13'I-hippuran (,"I-hip) klaring, als maat voor de efteolieve renale plasma 
flow (ERPF), en de '''l-thalamate ('''I-thai) klaring als maat voor de glomerulaire 
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filtratiesnelheid (GFR), werden gemeten voor en na een enkelvoudige hoge dosis DDAVP 
(400 nglkg Lv. in 10 minulen).De renale klaringen werden berekend uil de perileer-veneuze 
plasma spiegels en de infusie-snelheid van beide stoffen tijdens een continue infuus. De 
renale extractie-ratio's van 1311_hip (Et.;J en 125l-thal (E1hal) en de renale veno-arteriele renine 
ratio's van beide nieren werden afzonderlijk gemeten middels niervene-sampling voor en na 
DDAVP. De "'I_hip spiegel veranderde niel na DDAVP helgeen aangeeft dal de ERPF niel 
of nauwelijks was veranderd. Dus de signifioante daling van de Ehip die we vanden is 
waarschijnlijk veroorzaakt door een toename van de renale plasma flow (RPF). Deze RPF-
slijging vond plaals lelWijl de bloeddruk daalde. We concluderen daarom dal DDAVP, in de 
dosering die wij gebruikten, vaatverwijding in de nier veroorzaakte. 
De renale veno-arteriele renine--ratio's vertoonden een signifioante stijging. Oil toont 
aan dat de seoretie van renine door de nier is toegenomen, en dat hierdoor het peritere 
renine steeg. 
7.9 Conclusles 
Uit de studies, besohreven in dit proefschrift, kan worden geconoludeerd dat een 
hoge dosis DDAVP systemische en renale vaatverwijding veroorzaakt via V2-receptor 
stimulatie. De waargenomen effecten van lagere doseringen DDAVP geven aan dat V2-
reoeptor-gemedj{~erde vaatverwijding ook kan optreden onder bepaalde pathologisohe 
omstandigheden met verhoogde plasma-spiegels van endogeen AVP. Oergelijke sterk 
verhoogde AVP-spiegels worden gevonden wanneer het circulerend bloedvolume ernstig is 
verlaagd. Onder deze amstandigheden neemt de urine-productie at door stimulatie van V 2-
reoeptoren op de renale tubuluscellen, hetgeen helpt om het circulerend volume te 
bewaren. Vasooonstriotie door stimulatie van VI-receptoren veroorzaakt een sUjging van de 
perifere vaatweersland helgeen helpl om de bloeddruk op peil Ie houden. Hel is echler 
mogelijk dat V2-receptor-gemedieerde vaatverwijding dient als een mechanisme am vitale 
organen te beschermen tegen het vaatvernauwend effect van VI-receptor stimulatie. 
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NAWOORD 
Dil proefsohrift is voortgekomen uit klinisch wetenschappelijk onderzoek verricht op 
de aldeling Inwendige Geneeskunde I van hel Aoademisoh Ziekenhuis Dijkziglle 
Rollerdam. Uilsluilend door de belangeloze vrijwillige deelname aan de diverse 
experimenten van een aantal gezonde proefpersonen en patienten, en de inspanningen 
van aen aantal medewerkers van de afdeling was het mogelijk dit onderzoek Ie voltooien. 
Verder werd er een belangrijke bijdrage geleverd vanuil hel insliluul TNO-IVVO Ie Leiden 
alwaar een deel van de laboratorium·bepalingen werden verricht. AI die mensen die direct 
of indirect bij de totstandkoming van dit proefschrift betrokken zijn geweest wil ik in dit 
nawoord bedanken. Zander iemand tekort Ie willen doen wi! ik een aantal personan met 
name bedanken. 
Ais eersle mijn promolor Prof. Dr. M.A.D.H. Sohalekamp. Maarten, ik wit je bedanken 
voor de energie en lijd die je in mij hebl gernvesleerd zowellijdens als na mijn opleiding 101 
inlernis!. Je hebl me op weg geholpen op hel glibberige pad van hel klinisoh-
welensohappelijk onderzoek. Hel pad dal ik op jouw advies insloeg lag in een andere 
riohting dan de hoofdweg van het door jou geleidde onderzoek. Mede hierdoor was het 
vaor cns beiden niet eenvoudig de juiste route Ie vinden, eehter dankzij jouw inspanningen 
als gids is uileindelijk dil proelsohrifllol sland gekomen. 
Frans Derkx, door de jaren heen heb je, ondanks jauw ernstige preaccupatie met het 
renine-angiotensine-aldosteron systeem, steeds Hjd welen Ie vinden am mij Ie helpen met 
de vaortgang van het anderzoek. 
Rene de Bruin, de wijze waarop jij de gegevens van de diverse laboratorium-
bepalingen beheert was van onsehatbare waarde vaor het verzamelen van de data waarop 
dit proefsehrift is gebaseerd. 
Remeo Hooijer, een mengsel van kalk en azijn vormt de basis van een goeds 
vriendsohap. Zander jauw hulp met zowel hardware als software zou het schrijven van dit 
baekje aanzienlijk langer geduurd hebben. 
Pa, vaak is gebleken dal jij mij beler kende dan ik zelf wilde loegeven. Jouw niel 
a!lalende belangslelling heeft mij geslimuleerd om dil proelsohriH al Ie maken. 
Elly, mijn proelsohrift kon worden gesohreven dankzij hel leil dal jij aohler me slond. 
Jauw onbeperkt vertrouwen in het eindresultaat was voor mij de basis om door te gaan oak 
bij legenslag. Aan jou en onze kinderen wit ik dil proelsohrifl opdragen. 
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